研究者詳細

顔写真

オノデラ　コウイチ
小野寺　晃一
Koichi Onodera
所属
病院　内科　血液内科
職名
講師
学位

  • 医学博士 （東北大学）

経歴 2

  • 2025年6月 ～ 継続中
    東北大学病院　病院（医科診療部門） 血液内科　講師

  • 2021年6月 ～ 2025年8月
    東北大学病院　病院（医科診療部門） 血液内科　助教

所属学協会 3

  • 日本造血細胞移植学会

  • 日本内科学会

  • 日本血液学会

研究分野 1

  • ライフサイエンス / 血液、腫瘍内科学 /

論文 57

  1. Dual Targeting of Extramedullary Myeloma with Talquetamab and Teclistamab 国際誌

    Shaji Kumar, María-Victoria Mateos, Jing Christine Ye, Shebli Atrash, Hila Magen, Hang Quach, Michael P. Chu, Suzanne Trudel, Joshua Richter, Paula Rodríguez-Otero, Hun Chuah, Moshe Gatt, Eva Medvedova, Shahzad Raza, Dok Hyun Yoon, Tadao Ishida, Jeffrey V. Matous, Laura Rosiñol, Koichi Onodera, Emma Scott, Christoph Heuck, Jenny Zhang, Todd Henninger, Lisa O’Rourke, Payal Thakkar, Mariacristina Festa, Lin Huang, Jiangxiu Zhou, Mikihiro Takamoto, Lixia Pei, Jiashen Lu, Nicholas Au, Maria Krevvata, Saad Z. Usmani, Yael C. Cohen

    New England Journal of Medicine　2025年12月7日

    出版者・発行元： Massachusetts Medical Society

    DOI： 10.1056/nejmoa2514752 　

    ISSN：0028-4793

    eISSN：1533-4406

    詳細を見る 詳細を閉じる

    BACKGROUND: Patients with plasmacytomas that are noncontiguous with bone marrow (true extramedullary myeloma) are at high risk for disease progression or relapse. Phase 1 of the RedirecTT-1 study showed promising efficacy with dual-antigen targeting of myeloma with talquetamab (anti-G protein-coupled receptor family C group 5 member D) plus teclistamab (anti-B-cell maturation antigen) in patients with triple-class-exposed relapsed or refractory multiple myeloma, including those with true extramedullary myeloma. METHODS: In this phase 2 study, we investigated talquetamab plus teclistamab exclusively in patients with drug-resistant, true extramedullary myeloma. The primary end point was overall response, evaluated with the use of functional imaging. Secondary end points included the duration of response, progression-free survival, overall survival, and safety. RESULTS: A total of 90 patients were enrolled in the study and received treatment (median follow-up, 12.6 months). A response occurred in 79% of the patients (95% confidence interval [CI], 69 to 87). Among the patients with a response, the percentage with a response duration of at least 12 months was 64% (95% CI, 48 to 76). At 12 months, progression-free survival was 61% (95% CI, 50 to 71), and overall survival was 74% (95% CI, 63 to 83). Common adverse events of any grade included oral symptoms, such as dysgeusia, dry mouth, and dysphagia (in 87% of the patients); cytokine release syndrome (in 78%); and nonrash skin effects (in 69%). Grade 3 or 4 adverse events (most commonly hematologic events) occurred in 76% of the patients; 31% had grade 3 or 4 infection. A nonfatal adverse event led to discontinuation of one or both agents in 6% of the patients. Among 10 deaths that occurred during follow-up, 5 were due to infection and 5 were considered to be related to the study treatment. CONCLUSIONS: Most patients with drug-resistant, true extramedullary myeloma had a response with talquetamab plus teclistamab. The incidence of adverse events of grade 3 or above was high and was consistent with previous observations for each agent as monotherapy. (Funded by Johnson & Johnson; RedirecTT-1 ClinicalTrials.gov number, NCT04586426.).

  2. Mitapivat versus Placebo for Pyruvate Kinase Deficiency. 国際誌

    Hanny Al-Samkari, Frédéric Galactéros, Andreas Glenthøj, Jennifer A Rothman, Oliver Andres, Rachael F Grace, Marta Morado-Arias, D Mark Layton, Koichi Onodera, Madeleine Verhovsek, Wilma Barcellini, Satheesh Chonat, Malia P Judge, Erin Zagadailov, Rengyi Xu, Peter Hawkins, Vanessa Beynon, Sarah Gheuens, Eduard J van Beers

    The New England journal of medicine　386　(15)　1432-1442　2022年4月14日

    DOI： 10.1056/NEJMoa2116634 　

    詳細を見る 詳細を閉じる

    BACKGROUND: Pyruvate kinase deficiency is a rare, hereditary, chronic condition that is associated with hemolytic anemia. In a phase 2 study, mitapivat, an oral, first-in-class activator of erythrocyte pyruvate kinase, increased the hemoglobin level in patients with pyruvate kinase deficiency. METHODS: In this global, phase 3, randomized, placebo-controlled trial, we evaluated the efficacy and safety of mitapivat in adults with pyruvate kinase deficiency who were not receiving regular red-cell transfusions. The patients were assigned to receive either mitapivat (5 mg twice daily, with potential escalation to 20 or 50 mg twice daily) or placebo for 24 weeks. The primary end point was a hemoglobin response (an increase from baseline of ≥1.5 g per deciliter in the hemoglobin level) that was sustained at two or more scheduled assessments at weeks 16, 20, and 24. Secondary efficacy end points were the average change from baseline in the hemoglobin level, markers of hemolysis and hematopoiesis, and the change from baseline at week 24 in two pyruvate kinase deficiency-specific patient-reported outcome measures. RESULTS: Sixteen of the 40 patients (40%) in the mitapivat group had a hemoglobin response, as compared with none of the 40 patients in the placebo group (adjusted difference, 39.3 percentage points; 95% confidence interval, 24.1 to 54.6; two-sided P<0.001). Patients who received mitapivat had a greater response than those who received placebo with respect to each secondary end point, including the average change from baseline in the hemoglobin level. The most common adverse events were nausea (in 7 patients [18%] in the mitapivat group and 9 patients [23%] in the placebo group) and headache (in 6 patients [15%] and 13 patients [33%], respectively). Adverse events of grade 3 or higher occurred in 10 patients (25%) who received mitapivat and 5 patients (13%) who received placebo. CONCLUSIONS: In patients with pyruvate kinase deficiency, mitapivat significantly increased the hemoglobin level, decreased hemolysis, and improved patient-reported outcomes. No new safety signals were identified in the patients who received mitapivat. (Funded by Agios Pharmaceuticals; ACTIVATE ClinicalTrials.gov number, NCT03548220.).

  3. GATA2 regulates dendritic cell differentiation. 国際誌 査読有り

    Koichi Onodera, Tohru Fujiwara, Yasushi Onishi, Ari Itoh-Nakadai, Yoko Okitsu, Noriko Fukuhara, Kenichi Ishizawa, Ritsuko Shimizu, Masayuki Yamamoto, Hideo Harigae

    Blood　128　(4)　508-18　2016年7月28日

    DOI： 10.1182/blood-2016-02-698118 　

    ISSN：0006-4971

    eISSN：1528-0020

  4. Heme synthesis inhibition induces the intrinsic apoptosis pathway in leukemia with OSGIN1 upregulation

    Yan Yan, Hiroki Kato, Sayaka Sano, Eijiro Furukawa, Satoshi Ichikawa, Koichi Onodera, Yasushi Onishi, Noriko Fukuhara, Hisayuki Yokoyama, Tohru Fujiwara, Hideo Harigae

    Experimental Hematology　2026年5月

    DOI： 10.1016/j.exphem.2026.105401 　

  5. Loss-Prone HLA Class I Alleles Inform Outcomes of Early Hematopoietic Cell Transplantation in Acquired Aplastic Anemia. 国際誌

    Yoshitaka Zaimoku, Hirohito Yamazaki, Minoru Kanaya, Nobuhiro Hiramoto, Ken Ishiyama, Katsuto Takenaka, Makoto Murata, Naoyuki Uchida, Noriko Doki, Ryusuke Yamamoto, Testuya Nishida, Koichi Onodera, Shinichiro Machida, Yoshinobu Kanda, Tetsuya Eto, Keisuke Kataoka, Noboru Asada, Mitsuhiro Itagaki, Mamiko Sakata-Yanagimoto, Fumihiko Ishimaru, Makoto Onizuka, Tatsuo Ichinohe, Yoshiko Atsuta, Yasushi Onishi

    American journal of hematology　100　(12)　2195-2208　2025年12月

    DOI： 10.1002/ajh.70054 　

    詳細を見る 詳細を閉じる

    HLA class I allele loss in acquired aplastic anemia (AA) represents an immune escape from the T cell-mediated pathogenesis. We investigated the impact of loss-prone HLA alleles on the hematopoietic cell transplantation (HCT) outcomes using registry data of 875 Japanese patients with acquired AA. HLA associations were evident exclusively among 399 patients who received HCT within 1 year of the diagnosis, consistent with the predominance of HLA loss in this group. A set of five HLA alleles with the highest propensity for loss (HLA-A*02:01, HLA-A*02:06, HLA-A*31:01, HLA-B*40:02, and HLA-B*54:01) was the strongest predictor of post-transplant survival among all possible allele combinations (5-year survival, 80.3% vs. 54.4%; p < 0.0001), partly due to improved engraftment and pre-transplant conditions. Another set (HLA-A*33:03, HLA-B*07:02, HLA-B*44:03, HLA-B*52:01, and HLA-B*54:01)-less frequently lost in AA and underrepresented in Epstein-Barr virus (EBV)-related diseases outside AA-was associated with an increased risk of post-transplant lymphoproliferative disorders (5-year incidence, 10.2% vs. 1.8%; p = 0.00019), suggesting that the loss of protective alleles against EBV during AA pathogenesis may predispose to EBV-driven lymphoproliferations. These associations were determined by recipient, not donor, HLA. Therefore, specific HLA class I alleles and their potential loss significantly influence the HCT outcomes in acquired AA.

  6. Risk Factors for and Impact of Pre-Engraftment Syndrome on Outcomes Following Single-Unit Cord Blood Transplantation in Adults. 国際誌

    Masatoshi Sakurai, Keisuke Kataoka, Kota Mizuno, Takuto Mori, Shuichi Shirane, Hirotoshi Sakaguchi, Takehiko Mori, Masatsugu Tanaka, Masahito Tokunaga, Makoto Onizuka, Mamiko Sakata-Yanagimoto, Jun Ishikawa, Yuta Katayama, Shuichi Ota, Masashi Sawa, Jun Kato, Yuta Hasegawa, Koichi Onodera, Norimichi Hattori, Shigesaburo Miyakoshi, Nobuyuki Takayama, Tetsuya Nishida, Koji Kato, Fumihiko Ishimaru, Yoshiko Atsuta, Junya Kanda, Hideki Nakasone, Seitaro Terakura

    American journal of hematology　100　(12)　2248-2260　2025年12月

    DOI： 10.1002/ajh.70094 　

    詳細を見る 詳細を閉じる

    Pre-engraftment syndrome (PES) is a unique complication of cord blood transplantation (CBT) whose risk factors and impact on transplant outcomes remain controversial. Using a nationwide database in Japan, we analyzed a total of 3734 patients who underwent single-unit CBT. PES occurred in 18.3% of patients, and risk factors for PES included a higher hematopoietic cell transplantation-specific comorbidity index, first transplantation, myeloablative conditioning (MAC), lower total nucleated cell (TNC) dose, and graft-versus-host disease (GVHD) prophylaxis regimens excluding tacrolimus with methotrexate. Patients who developed PES had significantly higher incidences of grade II-IV acute GVHD (53.1% vs. 31.3%, p < 0.001) and chronic GVHD (27.2% vs. 21.7%, p = 0.002) compared to those without PES. Landmark analysis with multivariable adjustment revealed that PES was independently associated with increased non-relapse mortality (NRM, hazard ratio [HR] 1.46; 95% CI 1.22-1.75; p < 0.001), reduced relapse incidence (HR 0.78; 95% CI 0.63-0.96; p = 0.020), and a trend toward inferior overall survival (OS, HR 1.13; 95% CI 0.98-1.30; p = 0.088). Moreover, patients who experienced both PES and acute GVHD had the highest 2-year NRM (31.7%; 95% CI 26.0%-37.6%) and the lowest 2-year OS (55.9%; 95% CI 50.0%-62.4%), compared with those who experienced either PES (NRM 20.7%; OS 65.0%) or acute GVHD (NRM 19.5%; OS 62.8%) (p < 0.001), highlighting the combined effects of these complications. This study, the largest to date on PES, demonstrates its clinical significance as an early complication with lasting effects on transplant outcomes.

  7. Mixed-phenotype acute leukemia with trilineage differentiation presenting as a non-leukemic mediastinal tumor.

    Satoshi Ichikawa, Maya Yamato, Shusuke Hatta, Koichi Onodera, Noriko Fukuhara, Ryo Ichinohasama, Hideo Harigae

    Journal of clinical and experimental hematopathology : JCEH　2025年10月30日

    DOI： 10.3960/jslrt.25045 　

    詳細を見る 詳細を閉じる

    Mixed-phenotype acute leukemia (MPAL) is an uncommon hematological malignancy, and cases exhibiting trilineage differentiation are extraordinarily rare. Here, we report the case of a 63-year-old male patient who presented with severe dyspnea secondary to a massive anterior mediastinal mass and pleural effusion, in the absence of detectable abnormal cells in the peripheral blood. Immunophenotypic analysis of pleural fluid and tumor biopsy revealed an unprecedented trilineage phenotype with concurrent expression of T-lymphoid (cytoplasmic CD3+ and CD7+), B-lymphoid (CD19+ and CD22+), myeloid (cytoplasmic MPO+ and CD33+) markers, along with stem cell (CD34+ and HLA-DR+), and lymphoblastic (TdT+) markers. B-lineage commitment was further confirmed by immunoglobulin heavy chain gene rearrangement. These findings established a diagnosis of T/B/myeloid triphenotypic MPAL presenting as an aleukemic disease with minimal bone marrow infiltration (<1%). Initial treatment with acute myeloid leukemia-directed induction therapy (daunorubicin plus cytarabine) proved refractory. However, the hyperCVAD regimen, which is an acute lymphoblastic leukemia (ALL)-directed approach, achieved a complete metabolic response. Subsequent consolidation with cord blood transplantation resulted in durable remission lasting 2 years before a late relapse, which occurred in the mediastinal region. This is the first reported case of non-leukemic, triphenotypic MPAL presenting as a primary mediastinal tumor, highlighting the diagnostic complexity and therapeutic challenges associated with this rare malignancy. Based on our experience, intensive ALL-directed chemotherapy followed by allogeneic stem cell transplantation may offer an effective therapeutic strategy for this exceptionally rare clinical entity.

  8. Rare nodal involvement as the initial presentation of lymphomatoid granulomatosis, mimicking metastatic carcinoma. 国際誌

    Yuki Muroyama, Koichi Onodera, Akihisa Kawajiri, Takashi Suzuki, Ryo Ichinohasama

    Internal and emergency medicine　2025年10月28日

    DOI： 10.1007/s11739-025-04175-z 　

  9. High FCGR2B Expression Can Identify Low-tumor-burden Follicular Lymphoma Patients Who Do Not Require Any Antilymphoma Therapy for a Long Term. 国際誌

    Shotaro Watanabe, Hiroki Kato, Tohru Fujiwara, Shunsuke Hatta, Yasuo Tomiya, Koichi Onodera, Satoshi Ichikawa, Yasushi Onishi, Hisayuki Yokoyama, Fumiyoshi Fujishima, Ryo Ichinohasama, Hideo Harigae, Noriko Fukuhara

    The American journal of surgical pathology　49　(7)　740-747　2025年7月1日

    DOI： 10.1097/PAS.0000000000002397 　

    詳細を見る 詳細を閉じる

    Spontaneous regression or a long-term lack of obvious progression is often observed in patients with low-tumor-burden (LTB) follicular lymphoma (FL). However, conventional prognostic risk models are unable to precisely identify the patients who will not require any antilymphoma treatment for a long term, especially at diagnosis. In this study, we identified genes whose expression levels were associated with the clinical outcome of LTB FL and verified their prognostic value using immunohistochemistry. Because the tumor microenvironment may influence FL pathogenesis, we used digital expression profiling to quantify the expression of 730 immune-related genes extracted from tumor tissue specimens collected from 55 untreated patients with LTB FL. Five genes were identified as potential transcriptomic predictive markers. Among these, FCGR2B , an inhibitory FC gamma receptor, was immunohistochemically stainable and identified as a reliable immunohistochemical prognostic marker mainly expressed in tumor cells but not in the surrounding reactive cells. Our findings could help identify patients with LTB FL who do not require any antilymphoma treatment for the long term.

  10. Methotrexate-associated Angioimmunoblastic T-cell Lymphoma Presenting with Acute Kidney Injury.

    Satoshi Ichikawa, Hikaru Kumagai, Koichi Onodera, Yoko Okitsu, Masahiro Kobayashi, Shori Abe, Fumiyoshi Fujishima, Ryo Ichinohasama, Junichi Kameoka, Tomonori Ishii

    Internal medicine (Tokyo, Japan)　2025年6月19日

    DOI： 10.2169/internalmedicine.5578-25 　

    詳細を見る 詳細を閉じる

    A man in his 60s on methotrexate for rheumatoid arthritis developed a fever and lymph node swelling, suggesting a lymphoproliferative disorder. Methotrexate was discontinued; however, the patient was admitted for acute kidney injury (AKI) and thrombocytopenia. Blood tests showed high levels of inflammatory markers, positive plasma Epstein-Barr virus (EBV) DNA, and CD10-positive abnormal T cells, indicating T-cell neoplasm. CHOP chemotherapy with continuous hemodiafiltration improved the patient's condition. A lymph node biopsy confirmed the diagnosis of angioimmunoblastic T-cell lymphoma (AITL). To our knowledge, this is the first reported case of methotrexate-associated AITL complicated by AKI with a successful treatment course.

  11. Successful Allogeneic Hematopoietic Stem Cell Transplantation for Nodal Epstein-Barr Virus-positive T/NK-cell Lymphoma.

    Satoshi Ichikawa, Hiroaki Abe, Naoya Morota, Akihisa Kawajiri, Ryo Nakagawa, Kyoko Inokura, Shunsuke Hatta, Yuna Katsuoka, Koichi Onodera, Noriko Fukuhara, Yasushi Onishi, Hisayuki Yokoyama, Ryo Ichinohasama, Hideo Harigae

    Internal medicine (Tokyo, Japan)　64　(12)　1888-1892　2025年6月15日

    出版者・発行元： Japanese Society of Internal Medicine

    DOI： 10.2169/internalmedicine.4672-24 　

    ISSN：0918-2918

    eISSN：1349-7235

    詳細を見る 詳細を閉じる

    Nodal Epstein-Barr virus-positive T/NK-cell lymphoma (EB-nTNKL) is an extremely rare disease characterized by an aggressive clinical course and poor prognosis, for which treatment strategies have not yet been established. We herein report a young man with EB-nTNKL. Although initial chemotherapies, including L-asparaginase, failed to produce a good response, subsequent myeloablative allogeneic hematopoietic stem cell transplantation (alloHSCT) resulted in favorable disease control and a long-term disease-free survival. The prompt performance of alloHSCT using an available donor source at that time, regardless of whether or not the initial chemotherapy was effective, could be critical to saving patients with this otherwise fatal disease.

  12. Successful Cord Blood Transplantation for Myeloid/Natural Killer Precursor Acute Leukemia: A Case Report and Literature Review.

    Satoshi Ichikawa, Hiroaki Abe, Hiroka Komatsu, Kenta Takenaka, Hiroshi Nakamura, Naoya Morota, Kazuki Sakurai, Akihisa Kawajiri, Ryo Nakagawa, Kyoko Inokura, Koichi Onodera, Yasushi Onishi, Noriko Fukuhara, Hisayuki Yokoyama, Hideo Harigae

    Internal medicine (Tokyo, Japan)　64　(8)　1235-1239　2025年4月15日

    DOI： 10.2169/internalmedicine.4221-24 　

    詳細を見る 詳細を閉じる

    A 21-year-old man was diagnosed with myeloid/natural killer precursor leukemia (MNKPL) with bone marrow infiltration of blasts of cyCD3+, CD7+, CD33+, CD34dim, CD56+/-, HLA-DR+, cyMPO+, and TdT- immunophenotypes. Although hyper-CVAD therapy was unsuccessful, induction treatment with idarubicin and cytarabine resulted in complete remission (CR). The patient subsequently underwent cord blood transplantation with a myeloablative conditioning regimen, which resulted in durable CR and complete donor chimerism. He had been in good health without relapse for over nine months since transplantation. Timely allogeneic hematopoietic stem cell transplantation using an available donor source may be a promising treatment strategy for MNKPL.

  13. A phase 2 clinical trial of luspatercept in non-transfusion-dependent patients with myelodysplastic syndromes.

    Hiroshi Kosugi, Tomoaki Fujisaki, Hiromi Iwasaki, Atsushi Shinagawa, Hiroatsu Iida, Tatsuro Jo, Shiro Kubonishi, Yasuyoshi Morita, Yasuhiro Nakashima, Koichi Onodera, Kenshi Suzuki, Takahiro Suzuki, Yotaro Tamai, Kensuke Usuki, Akira Yokota, Hideyuki Yonaga, Jin Hayakawa, Shuichi Midorikawa, Mitsufumi Nishio, Makoto Suda, Kosei Matsue

    International journal of hematology　121　(1)　68-78　2025年1月

    DOI： 10.1007/s12185-024-03872-3 　

    詳細を見る 詳細を閉じる

    Luspatercept has shown durable clinical efficacy for the treatment of anemia in transfusion-dependent patients with lower-risk myelodysplastic syndromes (LR-MDS). We report the results of a prespecified primary analysis of a phase 2 trial of luspatercept in non-transfusion-dependent (NTD) Japanese patients with anemia due to LR-MDS. Luspatercept (starting dose 1.0 mg/kg) was administered subcutaneously once every 3 weeks. The primary endpoint was the proportion of patients who achieved hematological improvement-erythroid (HI-E) response (≥ 1.5 g/dL increase in hemoglobin level for 8 weeks) without transfusions within the first 24 weeks of treatment. At the primary analysis data cutoff, 21 patients had been enrolled/treated; 17 and 10 patients had completed 24 and 48 weeks of treatment, respectively. HI-E response occurred within 24 weeks in 10 patients (47.6%; 95% confidence interval, 25.7-70.2; P < 0.0001), which was significantly higher than the predefined threshold (10%). By week 48, HI-E response occurred in 12 patients (57.1%) and 17 patients (81.0%) remained NTD. Luspatercept was well tolerated. Three patients (14.3%) had grade 3-4 treatment-related treatment-emergent adverse events. Luspatercept resulted in statistically and clinically significant improvements in hemoglobin levels, and may help delay the need for transfusions in NTD patients with LR-MDS.

  14. Long-term remission following CAR-T therapy in a patient with transformed follicular lymphoma relapse after allogeneic stem cell transplantation. 国際誌

    Ryuta Kubo, Koichi Onodera, Yasushi Onishi, Noriko Fukuhara, Hideo Harigae

    Annals of hematology　104　(1)　841-845　2025年1月

    DOI： 10.1007/s00277-024-06150-8 　

    詳細を見る 詳細を閉じる

    Follicular lymphoma (FL) may undergo histological transformation (HT) into a more aggressive lymphoma. Although rituximab for B-cell non-Hodgkin lymphomas (B-NHL) has greatly improved the overall survival (OS) of patients with transformed FL (tFL), relapse after anthracycline-based chemoimmunotherapy has a poor prognosis. CD19-targeting chimeric antigen receptor-modified T-cell (CAR-T) therapy is a promising treatment for relapsed or refractory (r/r) large B-cell lymphoma (LBCL), including tFL. However, lymphopenia and reduced T-cell fitness caused by bendamustine exposure for treatment of underlying FL may impair the feasibility and reduce the efficacy of CAR-T therapy. Herein, we report the case of a 44-year-old woman with tFL who relapsed following allogeneic hematopoietic stem cell transplantation (allo-HSCT) and received CAR-T therapy. The patient could not initially undergo CAR-T therapy due to lymphopenia caused by bendamustine exposure, but CAR-T therapy became feasible following allo-HSCT. Although CAR-T therapy using T cells harvested from an allo-HSCT recipient may theoretically cause alloreactivity, the patient did not experience graft versus host disease (GVHD) or serious complications specific to CAR-T therapy, such as cytokine release syndrome (CRS) or immune effector cell-associated neurotoxicity syndrome (ICANS), and she has remained in complete response (CR) for >18 months. CAR-T therapy following allo-HSCT for patients with r/r tFL may be a safe and effective treatment option. Allo-HSCT may enhance the efficacy of CAR-T therapy.

  15. Comparing de novo chronic myeloid leukemia in blastic phase with Philadelphia chromosome-positive acute lymphoblastic leukemia after allogeneic hematopoietic cell transplantation. 国際誌

    Yosuke Okada, Noriaki Tachi, Yutaka Shimazu, Makoto Murata, Satoshi Nishiwaki, Yasushi Onishi, Atsushi Jinguji, Naoyuki Uchida, Masatsugu Tanaka, Yuta Hasegawa, Ayumu Ito, Shinichi Kako, Tetsuya Nishida, Koichi Onodera, Masashi Sawa, Hirohisa Nakamae, Masako Toyosaki, Yoshinobu Kanda, Makoto Onizuka, Takahiro Fukuda, Marie Ohbiki, Yoshiko Atsuta, Yasuyuki Arai, Takayoshi Tachibana

    Cancer　131　(1)　e35627　2025年1月1日

    DOI： 10.1002/cncr.35627 　

    詳細を見る 詳細を閉じる

    BACKGROUND: De novo chronic myeloid leukemia in blastic phase (CML-BP) showing lymphoid immunophenotype mimics Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph-positive ALL). Although upfront allogeneic hematopoietic cell transplantation (HCT) is considered in both diseases, it is not yet clear whether the transplant outcomes are also similar. METHODS: Using a registry database, the transplant outcomes between de novo CML-BP and Ph-positive ALL in negative-minimal residual disease (MRD), positive MRD, and nonremission cohorts were compared, respectively. All of the included patients had received tyrosine kinase inhibitor therapy before HCT and underwent HCT between 2002 and 2021. Regarding Ph-positive ALL, patients with p210 transcripts were excluded because there was concern that this group might include patients with de novo CML-BP. RESULTS: Although most of the outcomes were comparable, in patients with positive MRD at HCT, de novo CML-BP was significantly associated with superior disease-free survival (DFS) (hazard ratio [HR] 0.6, p = .0032), overall survival (HR 0.66, p = .027), and a lower risk of relapse (HR 0.48, p = .0051). In subgroup analyses, BCR::ABL1 mutation status had a significant interaction with the disease (p for interaction = .0027). De novo CML-BP seemed to be associated with superior disease-free survival in a BCR::ABL1 mutation-positive cohort, whereas this association was not observed in a mutation-negative cohort. CONCLUSIONS: Considering previous reports that showed inferior outcomes for de novo CML-BP compared to Ph-positive ALL, the data suggested that allogeneic HCT could overcome the poor prognosis of de novo CML-BP. These findings highlight the importance of distinguishing de novo CML-BP from Ph-positive ALL.

  16. Angioimmunoblastic T-cell lymphoma harboring a t(8;14)(q24;q11.2)/TCR::MYC translocation that presented with intestinal infiltration. 国際誌

    Satoshi Ichikawa, Hiroki Kato, Naoya Morota, Hiroaki Abe, Akihisa Kawajiri, Kyoko Inokura, Koichi Onodera, Yasushi Onishi, Noriko Fukuhara, Satoko Sato, Fumiyoshi Fujishima, Ryo Ichinohasama, Hideo Harigae

    Annals of hematology　104　(1)　835-840　2025年1月

    DOI： 10.1007/s00277-024-06148-2 　

    詳細を見る 詳細を閉じる

    Although rearrangement of the MYC oncogene (MYC-R) is frequently observed in aggressive B-cell lymphomas, it is extremely rare in T-cell malignancies. A 64-year-old man who had been under observation for several years because of asymptomatic pulmonary extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALToma) was admitted to our hospital because of poor general condition and hypotension. Blood tests revealed thrombocytopenia and elevated serum lactate dehydrogenase levels, whereas computed tomography revealed systemic lymphadenopathy and splenomegaly. An inguinal lymph node biopsy precipitated a diagnosis of angioimmunoblastic T-cell lymphoma (AITL). Shortly after admission, the patient experienced spontaneous intestinal perforation and hemorrhage caused by multiple intestinal infiltrations of the AITL. Although chemotherapy was administered, the patient died several weeks after admission. A 46,XY,t(8;14)(q24;q11.2) karyotype was identified, and fluorescence in situ hybridization analyses showed split signals for the MYC and T-cell receptor (TCR) alpha genes, by which a TCR::MYC translocation was confirmed. Pathological autopsy analysis revealed systemic infiltration of the AITL and no MALToma lesions. Only a few cases of mature T-cell lymphoma harboring MYC-R have been reported in the literature thus far. To the best of our knowledge, this is the first reported case of AITL with TCR::MYC rearrangement. This condition could be associated with refractoriness to chemotherapy and aggressive clinical course with systemic infiltration that included the intestine.

  17. Nivolumab-induced Thrombotic Thrombocytopenic Purpura in Patients with Gastric Tube Cancer.

    Yuya Yoshida, Sakura Toriyabe, Hiroo Imai, Keiju Sasaki, Yuki Kasahara, Kota Ouchi, Ken Saijo, Koichi Onodera, Chikashi Ishioka

    Internal medicine (Tokyo, Japan)　63　(19)　2667-2671　2024年10月1日

    DOI： 10.2169/internalmedicine.2931-23 　

    詳細を見る 詳細を閉じる

    Recently, immune checkpoint inhibitors (ICIs) have been used to treat several cancer types. ICIs have been reported to cause a wide variety of immune-related adverse events, including endocrine, neurologic, gastrointestinal, and cutaneous disorders. Thrombotic thrombocytopenic purpura (TTP) is an autoimmune hematologic disorder characterized by the presence of autoantibodies against a disintegrin and metalloprotease with thrombospondin-1, member 13. Several previous cases of TTP were thought to have been caused by ICI treatment. We herein report a rare case of TTP that developed after long-term treatment with an ICI (nivolumab) for gastric tube cancer.

  18. Significance of absolute neutrophil count before allogeneic hematopoietic stem cell transplantation in adult patients with aplastic anemia. 国際誌

    Yukinori Nakamura, Yoshitaka Zaimoku, Hiroki Yamaguchi, Hirohito Yamazaki, Minoru Kanaya, Naoyuki Uchida, Noriko Doki, Masatoshi Sakurai, Nobuhiro Hiramoto, Shinichi Kako, Makoto Onizuka, Koichi Onodera, Yumiko Maruyama, Hiroyuki Ohigashi, Tetsuya Nishida, Satoshi Yoshihara, Ken-Ichi Matsuoka, Tetsuya Eto, Yoshinobu Kanda, Takahiro Fukuda, Yoshiko Atsuta, Yasushi Onishi

    Annals of hematology　103　(8)　3121-3133　2024年8月

    DOI： 10.1007/s00277-024-05800-1 　

    詳細を見る 詳細を閉じる

    The impact of absolute neutrophil count (ANC) before allogenic hematopoietic stem cell transplantation (HSCT) on the outcomes for patients with aplastic anemia (AA) remains unclear. We retrospectively evaluated the relationship between ANC before transplantation and patient outcomes, involving 883 adult Japanese patients with AA who underwent allogeneic HSCT as their first transplantation between 2008 and 2020. Patients were divided into three groups based on ANC: 0/µL (n = 116); 1-199 (n = 210); and ≥ 200 (n = 557). In the low ANC groups (ANC < 200), patient age was higher, previous anti-thymocyte globulin (ATG) treatments were infrequent, duration from diagnosis to transplantation was shorter, hematopoietic cell transplantation-comorbidity index (HCT-CI) was higher, ATG-based conditioning was used infrequently, and peripheral blood stem cell from related donor and cord blood were used frequently. In multivariate analysis, patient age, previous ATG treatment, HCT-CI, stem cell source, and ANC before transplantation were significantly associated with 5-year overall survival (OS) ("ANC ≥ 200": 80.3% vs. "ANC 1-199": 71.7% vs. "ANC 0": 64.4%). The cumulative incidence of bacterial infection, invasive fungal disease, and early death before engraftment were significantly higher in the low ANC groups. Among patients with ANC of zero before transplantation, younger patient age, shorter duration from diagnosis to transplantation, HCT-CI of 0, and bone marrow from related donor as stem cell source were significantly associated with better OS. Consequently, ANC before allogeneic HSCT was found to be a significant prognostic factor in adult patients with AA. Physicians should pay attention to ANC before transplantation.

  19. Laparoscopic excision of accessory spleen for recurrent autoimmune hemolytic anemia after splenectomy: a case report.

    Ryosuke Kashiwagi, Masaharu Ishida, Koichi Onodera, Shuichi Aoki, Masahiro Iseki, Takayuki Miura, Hideo Ohtsuka, Masamichi Mizuma, Kei Nakagawa, Takashi Kamei, Michiaki Unno

    Surgical case reports　10　(1)　110-110　2024年5月3日

    DOI： 10.1186/s40792-024-01884-z 　

    詳細を見る 詳細を閉じる

    BACKGROUND: Splenectomy is indicated in cases of autoimmune hemolytic anemia (AIHA), which are refractory to medical management. In post-splenectomy, there exists a theoretical risk of AIHA recurrence, especially if an accessory spleen undergoes compensatory hypertrophy. In this context, we present a unique case of recurrent AIHA managed through laparoscopic excision of the accessory spleen (LEAS). CASE PRESENTATION: A 60-year-old male underwent laparoscopic splenectomy (LS) for AIHA refractory to standard medical therapies. Following the surgery, there was a marked improvement in hemolytic anemia symptoms, and oral steroid therapy was terminated 7 months post-LS. Nonetheless, a year after the LS, the patient exhibited a marked decline in hemoglobin levels, dropping to a concerning 5.8 g/dl, necessitating the reintroduction of oral steroids. A subsequent contrast-enhanced computed tomography (CT) scan unveiled an enlarged accessory spleen. The patient then underwent LEAS, during which the accessory spleen, obscured within adipose tissue, proved challenging to visualize laparoscopically. This obstacle was surmounted utilizing intraoperative ultrasonography (US), enabling successful excision of the accessory spleen. The post-surgical period progressed without complications, and the steroid dosage was reduced to one-twelfth of its initial preoperative quantity. CONCLUSIONS: Recurrent AIHA can be instigated by post-splenectomy compensatory hypertrophy of the accessory spleen. Ensuring comprehensive splenic tissue excision is crucial in AIHA management to obviate recurrent stemming from hypertrophic remnants. In scenarios of AIHA recurrence tied to an enlarged accessory spleen, LEAS stands as a viable and effective therapeutic modality.

  20. Impact of antithymocyte globulin usage and risk stratification for posttransplant lymphoproliferative disorders in aplastic anemia patients after allogeneic hematopoietic cell transplantation. 国際誌

    Ryusuke Yamamoto, Nobuhiro Hiramoto, Ayumi Fujimoto, Hirohito Yamazaki, Takehiko Mori, Naoyuki Uchida, Noriko Doki, Jun Kato, Masashi Nishikubo, Shinichi Kako, Tetsuya Nishida, Shuichi Ota, Makoto Onizuka, Tetsuya Eto, Koichi Onodera, Kazuhiro Ikegame, Ken-Ichi Matsuoka, Yoshinobu Kanda, Takahiro Fukuda, Yoshiko Atsuta, Yasushi Onishi

    Bone marrow transplantation　59　(5)　688-691　2024年5月

    DOI： 10.1038/s41409-024-02234-1 　

  21. Outcomes of Cessation of Nucleos(t)ide Analog Administration on Hepatitis B Virus Reactivation after Allogeneic Hematopoietic Stem Cell Transplantation: A Nationwide Retrospective Study. 国際誌

    Masahiro Onozawa, Shigeru Kusumoto, Yuho Najima, Hiroya Hashimoto, Kohei Okada, Masaharu Tamaki, Masatsugu Tanaka, Takayuki Sato, Tsutomu Takahashi, Kaoru Hatano, Koichi Onodera, Yukiyoshi Moriuchi, Kimikazu Yakushijin, Junya Kanda, Koji Nagafuji, Masao Ogata, Nobuaki Nakano, Akihiro Tamori, Masashi Mizokami

    Transplantation and cellular therapy　30　(3)　330.e1-330.e8　2024年3月

    DOI： 10.1016/j.jtct.2024.01.059 　

    詳細を見る 詳細を閉じる

    Monitoring of hepatitis B virus (HBV)-DNA and HBV-DNA-guided preemptive therapy using nucleos(t)ide analogs (NAs) are recommended to prevent the development of hepatitis due to HBV reactivation after allogeneic hematopoietic stem cell transplantation (allo-HSCT) in recipients with resolved HBV infection. However, little is known about the appropriate duration of NA treatment and the effect of NA cessation on the recurrence of HBV reactivation. This study aimed to clarify the consequences of NA cessation in allo-HSCT recipients with resolved HBV infection who experienced HBV reactivation following transplantation. We retrospectively reviewed the clinical records of recipients with resolved HBV infection (hepatitis B surface antigen [HBsAg]-negative, anti-HBc-positive) before allo-HSCT who had been diagnosed with HBV reactivation (HBsAg-positive and/or HBV-DNA detectable) after allo-HSCT between January 2010 and December 2020. A total of 72 patients from 16 institutions were registered (median age, 60 years; age range, 27 to 73 years; 42 males and 30 females). The day of initial HBV reactivation ranged from day 10 to day 3034 after allo-HSCT (median, 513 days). Anti-HBs were lost in >80% of the patients at the time of HBV reactivation. All 72 patients received preemptive NAs, and no fatal HBV reactivation-related hepatitis was observed. HBV-DNA without hepatitis was continuously detected in 5 patients during the follow-up period. Administration of NAs was discontinued in 24 of 72 patients (33%) by physician decision. Second HBV reactivation occurred in 11 of the 24 patients (46%) in whom administration of NAs was discontinued. The duration of NA treatment did not differ significantly between patients with or without second HBV reactivation. The frequency of further HBV reactivation tended to be lower in patients with an anti-HBs titer of >10 mIU/mL at the time of NA cessation. Multiple reactivations of HBV after NA cessation was common in patients with HBV reactivation who underwent allo-HSCT despite the long duration of NAs. Careful monitoring of HBV-DNA is important even after the discontinuation of NAs in the case with HBV reactivation after allo-HSCT, because multiple reactivations could occur. Active immunization by HB vaccine might be effective for suppressing further HBV reactivation after cessation of NAs.

  22. Erratum for Nivolumab-induced Thrombotic Thrombocytopenic Purpura in Patients with Gastric Tube Cancer.

    Yuya Yoshida, Sakura Toriyabe, Hiroo Imai, Keiju Sasaki, Yuki Kasahara, Kota Ouchi, Ken Saijo, Koichi Onodera, Chikashi Ishioka

    Internal medicine (Tokyo, Japan)　63　(24)　3407-3407　2024年

    DOI： 10.2169/internalmedicine.E003-24 　

  23. [Multiple myeloma with IgH::MYC and multiple extramedullary lesions].

    Yuto Sasaki, Satoshi Ichikawa, Kazuki Sakurai, Hiroshi Nakamura, Kyoko Inokura, Koichi Onodera, Noriko Fukuhara, Yasushi Onishi, Hisayuki Yokoyama, Hideo Harigae

    [Rinsho ketsueki] The Japanese journal of clinical hematology　65　(3)　147-152　2024年

    DOI： 10.11406/rinketsu.65.147 　

    詳細を見る 詳細を閉じる

    A 41-year-old woman with right shoulder pain was found to have multiple tumors with osteolysis and M-proteinemia. Abnormal plasma cells (CD38+, CD138+, Igλ≫κ) were detected in 1.4% of bone marrow nucleated cells, and G-banding analysis revealed a 46,XX,t (8;14), (q24;q32) karyotype in 4 of 20 cells analyzed. A biopsy specimen from an extramedullary lesion had a packed proliferation of aberrant plasmacytoid cells with positive IgH::MYC fusion signals on fluorescence in situ hybridization. The patient was diagnosed with symptomatic multiple myeloma and treated with the BLd regimen, which significantly reduced M protein levels. Extramedullary lesions were initially reduced, but increased again after four cycles. The lesions disappeared with subsequent EPOCH chemotherapy and radiation, and complete remission was confirmed. The patient was then treated with high-dose chemotherapy with autologous peripheral blood stem cell transplantation. Complete remission was maintained for over one year with lenalidomide maintenance therapy. A solitary IgH::MYC chromosomal translocation is extremely rare in multiple myeloma and may be associated with high tumor proliferative capacity, multiple extramedullary lesions, and poor prognosis. Combined therapeutic modalities with novel and conventional chemotherapy and radiation might be a promising treatment strategy for patients with this type of multiple myeloma.

  24. Plasma Venetoclax Concentrations in Patients with Acute Myeloid Leukemia Treated with CYP3A4 Inhibitors.

    Ayaka Otsuki, Masaki Kumondai, Daisuke Kobayashi, Masafumi Kikuchi, Yugo Ueki, Yuji Sato, Nagomi Hayashi, Ayaka Yagi, Yasushi Onishi, Koichi Onodera, Satoshi Ichikawa, Noriko Fukuhara, Hisayuki Yokoyama, Masamitsu Maekawa, Nariyasu Mano

    Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan　144　(7)　775-779　2024年

    DOI： 10.1248/yakushi.24-00018 　

    詳細を見る 詳細を閉じる

    Venetoclax (VEN) is used in patients with acute myeloid leukemia (AML) and is primarily metabolized by CYP3A4, a major drug-metabolizing enzyme. Patients with AML simultaneously administered VEN and CYP3A4 inhibitors require a more appropriate management of drug-drug interactions (DDIs). Here, we report two cases of patients with AML (54-year-old man and 22-year-old woman) administrated VEN and CYP3A4 inhibitors, such as posaconazole, cyclosporine, or danazol. In the first case, we evaluated the appropriateness of timing for adjusting VEN dosage subsequent to the cessation of posaconazole. Consequently, modifying the VEN dosage in conjunction with the cessation of Posaconazole simultaneously may result in elevated plasma VEN levels. In the second case, plasma VEN concentrations were markedly elevated when co-administered with several CYP3A4 inhibitors. Additionally, in vitro assays were conducted for reverse translational studies to analyze CYP3A4 inhibition. CYP3A4 inhibition by combinatorial administration of cyclosporine A and danazol was demonstrated in vitro, which potentially explains the increasing plasma VEN concentrations observed in clinical settings. Although the acquisition of therapeutic effects is a major priority for patients, frequent therapeutic drug monitoring and dosage adjustments considering DDIs would be important factors in chemotherapy.

  25. Comparison of Haploidentical Stem Cell Transplantation with Post-Transplantation Cyclophosphamide versus Umbilical Cord Blood Transplantation in Adult Patients with Aplastic Anemia. 国際誌

    Yasushi Onishi, Takehiko Mori, Hirohito Yamazaki, Nobuhiro Hiramoto, Yoshitaka Zaimoku, Minoru Kanaya, Kosei Matsue, Makoto Onizuka, Nobuyuki Aotsuka, Naoyuki Uchida, Koichi Onodera, Junya Kanda, Hirohisa Nakamae, Ryusuke Yamamoto, Takuro Kuriyama, Takafumi Kimura, Tatsuo Ichinohe, Yoshiko Atsuta

    Transplantation and cellular therapy　29　(12)　766.e1-766.e8　2023年12月

    DOI： 10.1016/j.jtct.2023.09.009 　

    詳細を見る 詳細を閉じる

    BACKGROUND: Aplastic anemia patients who are refractory to immunosuppressive therapy or with very low neutrophil counts require allogeneic hematopoietic stem cell transplantation (HSCT). Umbilical cord blood transplantation (UCBT) has been a treatment option when an HLA-matched donor is not available, and HSCT from a related haploidentical donor using post-transplant cyclophosphamide (PTCY) for GVHD prophylaxis (PTCY-haplo) recently became another important approach. OBJECTIVE: We aimed to compare the outcomes of PTCY-haplo and UCBT in adult patients with aplastic anemia in order to identify more effective and safer approaches for alternative donor transplantation. STUDY DESIGN: Data in a nationwide registry were retrospectively analyzed to assess the outcomes of aplastic anemia patients aged ≥16 years who received PTCY-haplo or UCBT as first HSCT between 2016 and 2020. The primary endpoint was 1-year overall survival (OS) after HSCT. Secondary endpoints included 1-year failure-free survival (FFS), neutrophil and platelet engraftment, and acute and chronic GVHD. RESULTS: Eighty-three patients who received PTCY-haplo (n = 24) and UCBT (n = 59) were eligible. One-year OS rates were 78.5% (95%CI, 55.7 - 90.5) in the PTCY-haplo group and 77.5% (95%CI, 64.5 - 86.3, P=0.895) in the UCBT group. One-year FFS rates were 78.7% (95%CI, 56.1 - 90.6) in the PTCY-haplo group and 62.2% (95%CI, 48.5 - 73.3, P=0.212) in the UCBT group. Among patients <40 years, the PTCY-haplo group had a significantly higher FFS rate; 92.9% (95%CI, 59.1 - 99.0) vs. 63.9% (95%CI, 43.2 - 78.7, P=0.047). Neutrophil and platelet engraftment rates were significantly higher in the PTCY-haplo group than in the UCBT group; 95.8% (95%CI, 73.9 - 99.4) vs. 78.0% (95%CI, 65.1 - 86.6, P<0.001) and 83.3% (95%CI, 61.5 - 93.4) vs. 72.9% (95%CI, 59.6 - 82.4, P=0.025). No significant difference was observed in the cumulative incidence of grade II-IV acute GVHD and chronic GVHD between the two groups. CONCLUSIONS: Aplastic anemia patients achieved significantly higher neutrophil and platelet engraftment rates with PTCY-haplo than with UCBT. OS and the incidence of acute and chronic GVHD were similar between the two groups. In patients <40 years, the FFS rate was higher in the PTCY-haplo group. Therefore, PTCY-haplo is promising for alternative donor transplantation in adult patients with aplastic anemia.

  26. Umbilical Cord Blood Transplantation for Myelodysplastic Syndromes with Donor-Specific Anti-HLA Antibodies against HLA-DP.

    Yusuke Uchibori, Koichi Onodera, Yasushi Onishi, Hiroka Komatsu, Kenta Takenaka, Yoshihiro Narumi, Tatsuya Watanabe, Hiroshi Nakamura, Kazuki Sakurai, Kazuki Hashimoto, Kyoko Inokura, Satoshi Ichikawa, Noriko Fukuhara, Hisayuki Yokoyama, Hideo Harigae

    The Tohoku journal of experimental medicine　261　(2)　123-127　2023年10月17日

    DOI： 10.1620/tjem.2023.J063 　

    詳細を見る 詳細を閉じる

    The presence of donor-specific anti-human leukocyte antigen (HLA) antibodies (DSAs) against anti-HLA-A, -B, -C, and -DRB1 in HLA-mismatched hematopoietic stem cell transplantation (HSCT) is associated with graft failure. DSAs against HLA-A, -B, -C, and -DRB1 with a mean fluorescence intensity (MFI) of greater than > 1,000 was shown to increase the risk of graft failure in single-unit umbilical cord blood transplantation (UCBT). Nevertheless, the impact of DSAs against HLA-DP or -DQ on transplantation outcomes is not fully understood. In this report, we present a case of UCBT in a patient with myelodysplastic syndrome who was positive for DSAs against HLA-DP with MFI of 1,263 before UCBT but successfully achieved neutrophil engraftment. If HLA-DP or -DQ is mismatched in UCBT, evaluating DSAs against HLA-DP or -DQ is crucial to avoid graft failure. However, the criteria for DSAs against HLA-A, -B, -C, and -DRB1 may not be directly applicable to those against HLA-DP or -DQ.

  27. Safety and efficacy of tisagenlecleucel in patients with relapsed or refractory B-cell lymphoma: the first real-world evidence in Japan.

    Hideki Goto, Toshio Kitawaki, Nobuharu Fujii, Koji Kato, Yasushi Onishi, Noriko Fukuhara, Takuji Yamauchi, Kazunori Toratani, Hiroki Kobayashi, Shota Yoshida, Masatoshi Shimo, Koichi Onodera, Hajime Senjo, Masahiro Onozawa, Kenji Hirata, Isao Yokota, Takanori Teshima

    International journal of clinical oncology　28　(6)　816-826　2023年6月

    DOI： 10.1007/s10147-023-02334-w 　

    詳細を見る 詳細を閉じる

    BACKGROUND: Tisagenlecleucel, an autologous CD19-directed T-cell immunotherapy, can induce a durable response in adult patients with relapsed/refractory (r/r) B-cell lymphoma. METHODS: To elucidate the outcome of chimeric antigen receptor (CAR) T-cell therapy in Japanese, we retrospectively analyzed the outcomes of 89 patients who received tisagenlecleucel for r/r diffuse large B-cell lymphoma (n = 71) or transformed follicular lymphoma (n = 18). RESULTS: With a median follow-up of 6.6-months, 65 (73.0%) patients achieved a clinical response. The overall survival (OS) and event-free survival (EFS) rates at 12 months were 67.0% and 46.3%, respectively. Overall, 80 patients (89.9%) had cytokine release syndrome (CRS), and 6 patients (6.7%) had a grade ≥ 3 event. ICANS occurred in 5 patients (5.6%); only 1 patient had grade 4 ICANS. Representative infectious events of any grade were cytomegalovirus viremia, bacteremia and sepsis. The most common other adverse events were ALT elevation, AST elevation, diarrhea, edema, and creatinine elevation. No treatment-related mortality was observed. A Sub-analysis showed that a high metabolic tumor volume (MTV; ≥ 80 ml) and stable disease /progressive disease before tisagenlecleucel infusion were both significantly associated with a poor EFS and OS in a multivariate analysis (P < 0.05). Notably, the combination of these 2 factors efficiently stratified the prognosis of these patients (HR 6.87 [95% CI 2.4-19.65; P < 0.05] into a high-risk group). CONCLUSION: We report the first real-world data on tisagenlecleucel for r/r B-cell lymphoma in Japan. Tisagenlecleucel is feasible and effective, even in late line treatment. In addition, our results support a new algorithm for predicting the outcomes of tisagenlecleucel.

  28. Elucidation of the Role of FAM210B in Mitochondrial Metabolism and Erythropoiesis. 国際誌

    Chie Suzuki, Tohru Fujiwara, Hiroki Shima, Koya Ono, Kei Saito, Hiroki Kato, Koichi Onodera, Satoshi Ichikawa, Noriko Fukuhara, Yasushi Onishi, Hisayuki Yokoyama, Yukio Nakamura, Kazuhiko Igarashi, Hideo Harigae

    Molecular and cellular biology　42　(12)　e0014322　2022年12月15日

    DOI： 10.1128/mcb.00143-22 　

    詳細を見る 詳細を閉じる

    Mitochondria play essential and specific roles during erythroid differentiation. Recently, FAM210B, encoding a mitochondrial inner membrane protein, has been identified as a novel target of GATA-1, as well as an erythropoietin-inducible gene. While FAM210B protein is involved in regulate mitochondrial metabolism and heme biosynthesis, its detailed function remains unknown. Here, we generated both knockout and knockdown of endogenous FAM210B in human induced pluripotent stem-derived erythroid progenitor (HiDEP) cells using CRISPR/Cas9 methodology. Intriguingly, erythroid differentiation was more pronounced in the FAM210B-depleted cells, and this resulted in increased frequency of orthochromatic erythroblasts and decreased frequencies of basophilic/polychromatic erythroblasts. Comprehensive metabolite analysis and functional analysis indicated that oxygen consumption rates and the NAD (NAD+)/NADH ratio were significantly decreased, while lactate production was significantly increased in FAM210B deletion HiDEP cells, indicating involvement of FAM210B in mitochondrial energy metabolism in erythroblasts. Finally, we purified FAM210B-interacting protein from K562 cells that stably expressed His/biotin-tagged FAM210B. Mass spectrometry analysis of the His/biotin-purified material indicated interactions with multiple subunits of mitochondrial ATP synthases, such as subunit alpha (ATP5A) and beta (ATP5B). Our results suggested that FAM210B contributes prominently to erythroid differentiation by regulating mitochondrial energy metabolism. Our results provide insights into the pathophysiology of dysregulated hematopoiesis.

  29. Exploring the mechanistic link between SF3B1 mutation and ring sideroblast formation in myelodysplastic syndrome. 国際誌

    Tetsuro Ochi, Tohru Fujiwara, Koya Ono, Chie Suzuki, Maika Nikaido, Daichi Inoue, Hiroki Kato, Koichi Onodera, Satoshi Ichikawa, Noriko Fukuhara, Yasushi Onishi, Hisayuki Yokoyama, Yukio Nakamura, Hideo Harigae

    Scientific reports　12　(1)　14562-14562　2022年8月26日

    DOI： 10.1038/s41598-022-18921-2 　

    詳細を見る 詳細を閉じる

    Acquired sideroblastic anemia, characterized by bone marrow ring sideroblasts (RS), is predominantly associated with myelodysplastic syndrome (MDS). Although somatic mutations in splicing factor 3b subunit 1 (SF3B1), which is involved in the RNA splicing machinery, are frequently found in MDS-RS, the detailed mechanism contributing to RS formation is unknown. To explore the mechanism, we established human umbilical cord blood-derived erythroid progenitor-2 (HUDEP-2) cells stably expressing SF3B1K700E. SF3B1K700E expressing cells showed higher proportion of RS than the control cells along with erythroid differentiation, indicating the direct contribution of mutant SF3B1 expression in erythroblasts to RS formation. In SF3B1K700E expressing cells, ABCB7 and ALAS2, known causative genes for congenital sideroblastic anemia, were downregulated. Additionally, mis-splicing of ABCB7 was observed in SF3B1K700E expressing cells. ABCB7-knockdown HUDEP-2 cells revealed an increased frequency of RS formation along with erythroid differentiation, demonstrating the direct molecular link between ABCB7 defects and RS formation. ALAS2 protein levels were obviously decreased in ABCB7-knockdown cells, indicating decreased ALAS2 translation owing to impaired Fe-S cluster export by ABCB7 defects. Finally, RNA-seq analysis of MDS clinical samples demonstrated decreased expression of ABCB7 by the SF3B1 mutation. Our findings contribute to the elucidation of the complex mechanisms of RS formation in MDS-RS.

  30. Long-term remission of primary refractory ALK-positive anaplastic large cell lymphoma after allogeneic hematopoietic stem cell transplantation.

    Masahiro Miyazaki, Satoshi Ichikawa, Yasushi Onishi, Noriko Fukuhara, Eijiro Furukawa, Koichi Onodera, Hisayuki Yokoyama, Ryo Ichinohasama, Hideo Harigae

    Journal of clinical and experimental hematopathology : JCEH　62　(3)　164-168　2022年6月22日

    DOI： 10.3960/jslrt.22003 　

    詳細を見る 詳細を閉じる

    ALK-positive anaplastic large cell lymphoma (ALK+ ALCL) has a favorable prognosis in general; however, some cases are resistant to chemotherapy, which leads to a poor clinical outcome. We herein report the case of a 32-year-old male with aggressive ALK+ ALCL who presented with hemorrhage from a large tumor in the duodenum and multiple tumors in the lungs, mediastinum, and peritoneal cavity. Although induction chemotherapy resulted in a marked reduction of the tumor lesions, premature progression with massive pulmonary infiltration and central nervous system invasion occurred immediately after the completion of chemotherapy. The patient was then promptly treated with brentuximab vedotin (BV) and high-dose methotrexate, which resulted in complete remission. Subsequently, he successfully underwent allogeneic hematopoietic stem cell transplantation (allo-HSCT) from an unrelated donor and has been healthy and did not relapse for more than 3 years after transplantation without any additional therapy. Allo-HSCT may be a promising treatment option for ALK+ ALCL due to its graft-versus-lymphoma effect. In addition, molecular targeting agents, such as BV, may be promising as a bridging therapy before allo-HSCT to achieve disease remission.

  31. Congenital sideroblastic anemia model due to ALAS2 mutation is susceptible to ferroptosis. 国際誌

    Koya Ono, Tohru Fujiwara, Kei Saito, Hironari Nishizawa, Noriyuki Takahashi, Chie Suzuki, Tetsuro Ochi, Hiroki Kato, Yusho Ishii, Koichi Onodera, Satoshi Ichikawa, Noriko Fukuhara, Yasushi Onishi, Hisayuki Yokoyama, Rie Yamada, Yukio Nakamura, Kazuhiko Igarashi, Hideo Harigae

    Scientific reports　12　(1)　9024-9024　2022年5月30日

    DOI： 10.1038/s41598-022-12940-9 　

    詳細を見る 詳細を閉じる

    X-linked sideroblastic anemia (XLSA), the most common form of congenital sideroblastic anemia, is caused by a germline mutation in the erythroid-specific 5-aminolevulinate synthase (ALAS2) gene. In XLSA, defective heme biosynthesis leads to ring sideroblast formation because of excess mitochondrial iron accumulation. In this study, we introduced ALAS2 missense mutations on human umbilical cord blood-derived erythroblasts; hereafter, we refer to them as XLSA clones. XLSA clones that differentiated into mature erythroblasts showed an increased frequency of ring sideroblast formation with impaired hemoglobin biosynthesis. The expression profiling revealed significant enrichment of genes involved in ferroptosis, which is a form of regulated cell death induced by iron accumulation and lipid peroxidation. Notably, treatment with erastin, a ferroptosis inducer, caused a higher proportion of cell death in XLSA clones. XLSA clones exhibited significantly higher levels of intracellular lipid peroxides and enhanced expression of BACH1, a regulator of iron metabolism and potential accelerator of ferroptosis. In XLSA clones, BACH1 repressed genes involved in iron metabolism and glutathione synthesis. Collectively, defective heme biosynthesis in XLSA clones could confer enhanced BACH1 expression, leading to increased susceptibility to ferroptosis. The results of our study provide important information for the development of novel therapeutic targets for XLSA.

  32. TM5614, an Inhibitor of Plasminogen Activator Inhibitor-1, Exerts an Antitumor Effect on Chronic Myeloid Leukemia.

    Katsuyuki Sasaki, Tohru Fujiwara, Tetsuro Ochi, Koya Ono, Hiroki Kato, Koichi Onodera, Satoshi Ichikawa, Noriko Fukuhara, Yasushi Onishi, Hisayuki Yokoyama, Toshio Miyata, Hideo Harigae

    The Tohoku journal of experimental medicine　257　(3)　211-224　2022年4月28日

    DOI： 10.1620/tjem.2022.J036 　

    詳細を見る 詳細を閉じる

    Chronic myeloid leukemia (CML) is triggered by t(9;22)(q34;q11.2) translocation, leading to the formation of the BCR-ABL1 fusion gene. Although the development of BCR-ABL1 tyrosine kinase inhibitors (TKIs) has dramatically improved the prognosis of CML, the disease could often relapse, presumably because leukemic stem cell fraction of CML (CML-LSC) may reside in specific niches, and also acquire an ability to resist the cytotoxic agents. Recently a study indicated that pharmacological inhibition of plasminogen activator inhibitor-1 (PAI-1, also known as SERPINE1) would cause detachment of CML-LSCs from their niche by inducing maturation of membrane-type matrix metalloprotease-1 (MT1-MMP), leading to increased susceptibility of CML-LSCs against TKIs. However, the direct antitumor effect of PAI-1 inhibition in CML remains unclear. Because PAI-1 mRNA expression was lower in CML cell line (K562) than bone marrow mononuclear cells derived from CML patients, we established K562 cell clones stably expressing exogenous PAI-1 (K562/PAI-1). We found that TM5614 treatment significantly suppressed cell proliferation and induced apoptosis in K562/PAI-1 cells, accompanied by increased activity of Furin protease, which is a known target of PAI-1. Besides processing mature MT1-MMP, Furin is in charge of cleaving the NOTCH receptor to form a heterodimer before exporting it to the cell surface membrane. In K562/PAI-1 cells, TM5614 treatment increased NOTCH1 intracellular domain (NICD) protein expression as well as NOTCH1 target of HEY1 mRNA levels. Finally, forced expression of either Furin or NICD in K562/PAI-1 cells significantly inhibited cell proliferation and induced apoptosis. Collectively, PAI-1 inhibition may have an antitumor effect by modulating the Furin/NICD pathway.

  33. Unrelated cord blood transplantation for adult-onset EBV-associated T-cell and NK-cell lymphoproliferative disorders.

    Yasushi Onishi, Koichi Onodera, Noriko Fukuhara, Hiroki Kato, Satoshi Ichikawa, Tohru Fujiwara, Hisayuki Yokoyama, Minami Yamada-Fujiwara, Hideo Harigae

    International journal of hematology　115　(6)　873-881　2022年3月10日

    DOI： 10.1007/s12185-022-03313-z 　

    詳細を見る 詳細を閉じる

    Adult-onset EBV-associated T-cell and NK-cell lymphoproliferative disorders (EBV-T/NK-LPDs) often progress rapidly, and require allogeneic stem cell transplantation early in the course of treatment. Unrelated cord blood transplantation (UCBT) is a readily available option for patients without HLA-matched donors. We retrospectively analyzed the outcomes of 12 UCBT in adult patients with chronic active EBV infection (CAEBV, n = 8), EBV-positive hemophagocytic lymphohistiocytosis following primary EBV infection (n = 2), hydroa vacciniforme-like lymphoproliferative disorder (n = 1), and systemic EBV-positive T-cell lymphoma of childhood (STCLC, n = 1). The median age at transplantation was 31.5 years (range 19-58). At the median follow-up time for survivors, which was 6.3 years (range 0.3-11.3), 3-year overall survival (OS) rates in all patients and 8 CAEBV patients were 68.2% (95% CI 28.6-88.9) and 83.3% (95% CI 27.3-97.5), respectively. Graft failure occurred in 4 of 8 CAEBV patients, requiring a second UCBT to achieve neutrophil engraftment. The cumulative incidence of grade II-IV acute GVHD was 33.3% (95% CI 9.1-60.4%). The EBV-DNA load became undetectable or very low after UCBT in all cases. UCBT may be a promising treatment option for adult-onset EBV-T/NK-LPDs.

  34. Aleukemic T-lymphoblastic leukemia/lymphoma with massive cerebrospinal fluid infiltration

    Ichikawa, S., Fukuhara, N., Doman, T., Kiba, D., Tanaka, Y., Inokura, K., Morota, N., Ono, K., Onodera, K., Onishi, Y., Yokoyama, H., Ichinohasama, R., Harigae, H.

    Journal of Hematopathology　15　(2)　105-109　2022年

    DOI： 10.1007/s12308-022-00495-7 　

    ISSN：1865-5785 1868-9256

    eISSN：1865-5785

  35. Diffuse Large B-cell Lymphoma Presenting as Peritoneal Lymphomatosis: A Case Report and Literature Review.

    Satoshi Ichikawa, Noriko Fukuhara, Kei Saito, Koichi Onodera, Yasushi Onishi, Hisayuki Yokoyama, Ryo Ichinohasama, Hideo Harigae

    Internal medicine (Tokyo, Japan)　61　(13)　2057-2060　2021年12月11日

    DOI： 10.2169/internalmedicine.8793-21 　

    詳細を見る 詳細を閉じる

    Peritoneal lymphomatosis (PL) is a rare presentation of malignant lymphoma cases, many of which are diagnosed as diffuse large B-cell lymphoma (DLBCL) and characterized by aggressive clinical courses. We herein report a 63-year-old woman presenting with the rapid development of abdominal distention due to bulky peritoneal tumors. The pathological evaluation of a needle biopsy sample, combined with flow cytometry, yielded the diagnosis of DLBCL. Prompt chemotherapeutic intervention resulted in favorable disease control and sustained complete remission. It is necessary to diagnose cases of DLBCL presenting as PL early to ensure prompt treatment and prevent mortality.

  36. 特集 貧血と諸疾患の機序を探る 巨赤芽球性貧血

    小野寺 晃一, 大西 康

    Pharma Medica　39　(11)　19-22　2021年11月20日

    出版者・発行元： メディカルレビュー社

    DOI： 10.34449/j0001.39.11_0019-0022 　

    ISSN：0289-5803

  37. T-cell receptor-silent peripheral T-cell lymphoma complicated with hemophagocytic lymphohystiocytosis. 国際誌

    Koya Ono, Yasushi Onishi, Koichi Onodera, Daigo Michimata, Eijiro Furukawa, Kazuki Sakurai, Naoya Morota, Takumi Sawada, Satoshi Ichikawa, Noriko Fukuhara, Hisayuki Yokoyama, Hirofumi Watanabe, Chie Suzuki, Hideo Harigae

    Annals of hematology　101　(4)　901-903　2021年8月30日

    DOI： 10.1007/s00277-021-04628-3 　

  38. Second direct-acting antiviral therapy for hepatitis C virus infection after umbilical cord blood transplantation: A case report. 国際誌 査読有り

    Koichi Onodera, Yasushi Onishi, Jun Inoue, Yuya Tanaka, Lee Yonha, Satoshi Ichikawa, Noriko Fukuhara, Hisayuki Yokoyama, Kazunori Murai, Atsushi Masamune, Hideo Harigae

    Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy　27　(8)　1230-1233　2021年8月

    DOI： 10.1016/j.jiac.2021.02.002 　

    詳細を見る 詳細を閉じる

    Hepatitis C virus (HCV) infection has an adverse impact on outcomes after allogeneic hematopoietic stem cell transplantation (HSCT). It is recommended that HSCT candidates infected with HCV receive the treatment prior to transplantation. Although the recent approval of direct-acting antivirals (DAAs) has led to great advances in the treatment of HCV infection, little information is available on the efficacy and safety of DAA therapy in patients receiving allogeneic HSCT. Herein, we report the clinical course of an umbilical cord blood (UCB) recipient treated with DAAs for HCV infection. The patient achieved HCV RNA negativity with glecaprevir and pibrentasvir after consolidation therapy for acute myeloid leukemia (AML), and underwent transplantation before confirming sustained virological response (SVR) at 12 weeks. The HCV viral load became detectable on day +28 after transplantation and second HCV treatment with sofosbuvir, velpatasvir, and ribavirin was required. It is important to confirm SVR prior to transplantation, but it is often difficult. If early transplantation is required, close monitoring of HCV RNA after transplantation is needed. Further investigation is required to clarify the optimal management of HCV infection for allogeneic HSCT recipients in the DAA era.

  39. High-throughput liquid chromatography/electrospray ionization-tandem mass spectrometry method using in-source collision-induced dissociation for simultaneous quantification of imatinib, dasatinib, bosutinib, nilotinib, and ibrutinib in human plasma. 国際誌 査読有り

    Tensei Hirasawa, Masafumi Kikuchi, Kensuke Shigeta, Shinya Takasaki, Yu Sato, Toshihiro Sato, Jiro Ogura, Koichi Onodera, Noriko Fukuhara, Yasushi Onishi, Masamitsu Maekawa, Nariyasu Mano

    Biomedical chromatography : BMC　35　(8)　e5124　2021年3月27日

    DOI： 10.1002/bmc.5124 　

    詳細を見る 詳細を閉じる

    Recent studies have shown that therapeutic drug monitoring of tyrosine kinase inhibitors (TKIs) could improve treatment efficacy and safety. A simple analytical method using high-performance LC/electrospray ionization-tandem mass spectrometry has been developed and validated for simultaneous quantification of BCR-ABL and Bruton's TKIs used for chronic leukemia (imatinib, dasatinib, bosutinib, nilotinib, and ibrutinib) in human plasma. Although these structures and physical properties are similar, owing to their different linear ranges, simultaneously determining the plasma levels of these five TKIs by applying optimal MS parameters remains difficult. A quantitative range exceeding 60,000-fold was required, and the linear dynamic ranges of imatinib, bosutinib, and nilotinib were limited because of the presence of a saturated detection signal. In this study, we applied the in-source collision-induced dissociation technique to control the ion amounts in mass spectrometry. This new method allowed rapid determination within 5 min with simple pretreatment. The method was validated according to the US Food and Drug Administration guidelines. Moreover, all samples of patients with chronic leukemia were successfully measured and their values were within the linear range of measurement. Therefore, our high-throughput analytical system is useful to measure the plasma concentrations of imatinib, dasatinib, bosutinib, nilotinib, and ibrutinib in clinical practice.

  40. BK Virus-Associated Urothelial Carcinoma in a Patient with Peripheral Blood Stem Cell Transplantation for Acute Lymphoblastic Leukemia: A Case Report 国際誌 査読有り

    Juntaro Koyama, Yoshihide Kawasaki, Shingo Kimura, Takuma Sato, Shuichi Shimada, Naoki Kawamorita, Shinichi Yamashita, Ryo Nakagawa, Akihisa Kawajiri, Koichi Onodera, Yasushi Onishi, Koji Mitsuzuka, Mika Watanabe, Akihiro Ito

    Case Reports in Oncology　14　(1)　8-12　2021年1月11日

    出版者・発行元： S. Karger AG

    DOI： 10.1159/000511053 　

    eISSN：1662-6575

    詳細を見る 詳細を閉じる

    Bladder tamponade due to hemorrhagic cystitis caused by BK virus in immunocompetent patients is familiar to urologists. BK virus is an important cause of nephropathy and graft loss in kidney transplant recipients. Although urothelial carcinoma of the bladder in kidney transplant recipients with persistent BK viruria is known, BK virus-associated urothelial carcinoma (BKVUC) in peripheral blood stem cell transplantation recipients is not as well known. A 54-year-old man with acute lymphoblastic leukemia was treated in the Department of Hematology of our hospital. After recurrence 25 months later, he received chemotherapy for half a year and underwent peripheral blood stem cell transplantation. He achieved temporarily complete remission, but he developed hematuria with BK virus-positive result 1 month after peripheral blood stem cell transplantation. One month later, he developed bladder tamponade-diagnosed hemorrhagic cystitis due to BK virus in our Urological Department. We performed transurethral coagulation to manage hemorrhage and removed a bleeding lesion in the bladder wall. Pathological examination of the removed bladder wall revealed pT1 stage BKVUC. We found that bladder tamponade could have led to reactivation of BK virus in this immunocompetent patient. This could be the first report of BKVUC of the bladder found in a peripheral blood stem cell transplantation recipient with close urological follow-up for 24 months. Adequate removal of bleeding lesions from the bladder mucosa with appropriate timing during hemorrhagic cystitis due to BKVUC could be essential to achieve good outcomes.

  41. Salvage Cord Blood Transplantation for Sustained Remission of Acute Megakaryoblastic Leukemia That Relapsed Early after Myeloablative Transplantation

    Satoshi Ichikawa, Tohru Fujiwara, Kei Saito, Kazuki Sakurai, Kyoko Inokura, Noriko Fukuhara, Hisayuki Yokoyama, Koichi Onodera, Yasushi Onishi, Junichi Kameoka, Hideo Harigae

    Internal Medicine　60　(18)　3015-3019　2021年

    DOI： 10.2169/internalmedicine.6796-20 　

    ISSN：0918-2918

    eISSN：1349-7235

  42. Successful Treatment of Primary Refractory Angioimmunoblastic T-cell Lymphoma With Cord Blood Transplantation. 国際誌 査読有り

    Satoshi Ichikawa, Noriko Fukuhara, Kei Saito, Eijiro Furukawa, Koichi Onodera, Yasushi Onishi, Hisayuki Yokoyama, Ryo Ichinohasama, Hideo Harigae

    Clinical lymphoma, myeloma & leukemia　20　(11)　e926-e929　2020年11月

    DOI： 10.1016/j.clml.2020.07.009 　

  43. A novel case of γδ T cell leukemia with recurrent genetic abnormalities accompanied by agranulocytosis. 国際誌 査読有り

    Satoshi Ichikawa, Tohru Fujiwara, Kei Saito, Noriko Fukuhara, Hisayuki Yokoyama, Shunsuke Hatta, Koichi Onodera, Yasushi Onishi, Fumiyoshi Fujishima, Ryo Ichinohasama, Hideo Harigae

    Annals of hematology　100　(10)　2665-2668　2020年8月31日

    DOI： 10.1007/s00277-020-04241-w 　

  44. Sustained remission of giant pancreatic plasmacytoma with daratumumab. 国際誌 査読有り

    Satoshi Ichikawa, Eijiro Furukawa, Kei Saito, Noriko Fukuhara, Koichi Onodera, Yasushi Onishi, Hisayuki Yokoyama, Ryo Ichinohasama, Hideo Harigae

    Annals of hematology　100　(10)　2633-2634　2020年6月18日

    DOI： 10.1007/s00277-020-04145-9 　

  45. Epstein-Barr virus-positive diffuse large B-cell lymphoma after sustained remission of T-cell prolymphocytic leukemia with alemtuzumab. 国際誌 査読有り

    Satoshi Ichikawa, Noriko Fukuhara, Kei Saito, Hisayuki Yokoyama, Koichi Onodera, Yasushi Onishi, Ryo Ichinohasama, Hideo Harigae

    Leukemia & lymphoma　61　(6)　1504-1507　2020年6月

    DOI： 10.1080/10428194.2020.1713322 　

  46. Successful Treatment of Life-threatening Bleeding Caused by Acquired Factor X Deficiency Associated with Respiratory Infection. 査読有り

    Satoshi Ichikawa, Kei Saito, Noriko Fukuhara, Yuya Tanaka, Yoonha Lee, Koichi Onodera, Yasushi Onishi, Hisayuki Yokoyama, Minami Fujiwara, Hideo Harigae

    Internal medicine (Tokyo, Japan)　59　(10)　1303-1308　2020年5月15日

    DOI： 10.2169/internalmedicine.4142-19 　

    詳細を見る 詳細を閉じる

    Acquired factor X deficiency (AFXD) is a very rare coagulation disorder. A 40-year-old man with no comorbidities suffering from a fever, malaise, and severe hemorrhagic symptoms, including massive hematuria, was emergently admitted. His platelet count was normal, but his prothrombin time and activated partial thromboplastin time were markedly prolonged, which was thought to be due to autoantibody against a coagulation factor in the common pathway. Despite severe massive hematuria resulting in transient renal failure, he was successfully treated with urgent immunosuppressive therapy. Computed tomography revealed bronchopneumonia, which improved with antibiotic administration. AFXD without evidence of amyloidosis was subsequently diagnosed.

  47. Successful treatment of methotrexate-associated classical Hodgkin lymphoma with brentuximab vedotin-combined chemotherapy: a case series. 査読有り

    Satoshi Ichikawa, Noriko Fukuhara, Kei Saito, Koichi Onodera, Tsuyoshi Shirai, Yasushi Onishi, Hisayuki Yokoyama, Hiroshi Fujii, Ryo Ichinohasama, Hideo Harigae

    International journal of hematology　111　(5)　667-672　2020年5月

    DOI： 10.1007/s12185-020-02822-z 　

    詳細を見る 詳細を閉じる

    Methotrexate (MTX)-associated classical Hodgkin lymphoma (CHL) is unlikely to regress following discontinuation of MTX, and its treatment usually requires chemotherapy. Standard chemotherapy for CHL is the ABVD regimen, which contains pneumotoxic bleomycin. This can be problematic in MTX-CHL patients suffering from an autoimmune disease (AID), such as rheumatoid arthritis (RA), as they frequently have pulmonary complications. However, brentuximab vedotin (BV)-containing chemotherapy without bleomycin (A + AVD regimen) was recently reported to show favorable efficacy for CHL, and could therefore be beneficial in MTX-CHL. We treated three cases of MTX-CHL using the A + AVD regimen. All were female and had received MTX for more than 15 years. Underlying AIDs in these patients were RA in two patients, and overlap syndrome with systemic lupus erythematosus and dermatomyositis in one patient. The A + AVD regimen resulted in a complete response in all patients. Peripheral neuropathy developed in two patients, necessitating reduction of the BV dose. All three patients experienced hematological toxicity necessitating dose reduction; however, no severe adverse effects, including infection or pulmonary complication, were documented. RA was well-controlled without additional immunosuppressants. The A + AVD regimen is a promising chemotherapy for MTX-CHL with favorable efficacy and tolerable toxicity profiles.

  48. Long-term survival after cord blood transplantation for acute myeloid leukemia complicated with disseminated fusariosis. 国際誌 査読有り

    Satoshi Ichikawa, Noriko Fukuhara, Shotaro Watanabe, Yoko Okitsu, Koichi Onodera, Yasushi Onishi, Hideo Harigae

    Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy　26　(2)　292-295　2020年2月

    DOI： 10.1016/j.jiac.2019.08.022 　

    ISSN：1341-321X

    詳細を見る 詳細を閉じる

    Fusariosis is a critical infectious complication that can develop in immunocompromised hosts, mainly under conditions of prolonged neutropenia, and is often disseminated and associated with a high mortality rate. Disseminated fusariosis developing during the course of hematopoietic stem cell transplantation (HSCT) is a critical condition, and there have been few reports of successful treatment of cases complicated with fusariosis before HSCT. Here, we present a case of acute myeloid leukemia (AML) with the development of fungal endophthalmitis during chemotherapy. Vitrectomy was performed and Fusarium solani infection was confirmed by vitreal culture. The infection was also disseminated to the lung, triceps, and spleen. The splenic lesions disappeared with the administration of antifungal agents, and residual lesions in the lung and triceps were surgically resected. After two courses of consolidation chemotherapy, the patient received cord blood transplantation (CBT) twice because of graft failure in the first transplantation. Antifungal agents were administered continuously during chemotherapy and transplantation. Although Fusarium sinusitis developed after neutrophil engraftment, it was well controlled by surgical resection. Thereafter, the patient has been well without recurrence of fusariosis for more than 2 years since transplantation. A combination of continuous administration of antifungal agents and vigorous surgical intervention may be important for management of disseminated fusariosis in the setting of HSCT.

  49. Primary adrenal extranodal NK/T-cell lymphoma: A case report and literature review. 国際誌

    Satoshi Ichikawa, Kei Saito, Noriko Fukuhara, Hisayuki Yokoyama, Koichi Onodera, Yasushi Onishi, Ryo Ichinohasama, Hideo Harigae

    Leukemia research reports　14　100223-100223　2020年

    DOI： 10.1016/j.lrr.2020.100223 　

    詳細を見る 詳細を閉じる

    A 37-year-old man was admitted to our department following the detection of bulky tumors in his bilateral adrenal glands. A biopsy resulted in the diagnosis of extranodal NK/T cell lymphoma, nasal type (ENKL). After debulking by chemotherapy, allogeneic hematopoietic stem cell transplantation (alloHCT) was performed. Relapses in the liver and adrenal glands were identified 2 months post alloHCT, for which temporary administration of l-asparaginase resulted in complete metabolic response. However, multiple relapses in the central nervous system and lethal lymphomatous meningitis successively developed. Primary adrenal ENKL could tend to present as bulky lesion and follow an aggressive clinical course.

  50. Preemptive therapy for cytomegalovirus reactivation after daratumumab-containing treatment in patients with relapsed and refractory multiple myeloma. 国際誌 査読有り

    Ryo Nakagawa, Yasushi Onishi, Akihisa Kawajiri, Koichi Onodera, Eijiro Furukawa, Sayaka Sano, Kei Saito, Satoshi Ichikawa, Tohru Fujiwara, Noriko Fukuhara, Hideo Harigae

    Annals of hematology　98　(8)　1999-2001　2019年8月

    DOI： 10.1007/s00277-019-03645-7 　

    ISSN：0939-5555

  51. Umbilical Cord Blood Transplantation Using Reduced-Intensity Conditioning without Antithymocyte Globulin in Adult Patients with Severe Aplastic Anemia. 国際誌 査読有り

    Tetsuro Ochi, Yasushi Onishi, Kentaro Nasu, Koichi Onodera, Masahiro Kobayashi, Satoshi Ichikawa, Tohru Fujiwara, Noriko Fukuhara, Minami Yamada-Fujiwara, Hideo Harigae

    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation　25　(2)　e55-e59-e59　2019年2月

    DOI： 10.1016/j.bbmt.2018.09.039 　

    ISSN：1083-8791

    詳細を見る 詳細を閉じる

    Umbilical cord blood transplantation (UCBT) is a possible option for patients with aplastic anemia (AA) without a related or unrelated HLA-matched donor, particularly if immunosuppressive therapy (IST) has failed or transplantation is urgently needed. However, a higher rate of graft failure after UCBT remains a major problem, and the optimal conditioning regimen for stable engraftment after UCBT has not been established. Here we investigated 6 adult patients with AA who underwent UCBT using a reduced-intensity conditioning (RIC) regimen comprising fludarabine 125 mg/m2, cyclophosphamide 120 mg/kg, and 4 Gy of total body irradiation (Flu/CY/TBI4Gy) without antithymocyte globulin (ATG). Five patients underwent UCBT after IST failure, and 1 patient underwent UCBT as a first-line treatment due to a fulminant clinical finding of a neutrophil count of 0, despite granulocyte colony-stimulating factor administration. Regarding graft-versus-host disease (GVHD) prophylaxis, 2 patients received tacrolimus plus short-term methotrexate and 4 patients received tacrolimus plus mycophenolate mofetil, and all patients achieved sustained engraftment of both neutrophils and platelets, at a median of 17.5 days (range, 14 to 37 days) and 38.5 days (range, 31 to 86 days), respectively, with complete donor chimerism confirmed in all patients at a median of 14 days (range, 14 to 32 days). Three patients developed grade II acute GVHD (aGVHD), but grade III/IV aGVHD was not observed, whereas 4 patients developed chronic GVHD involving only skin. At the time of this report, all 6 patients were alive without the need for blood transfusion, at a median follow-up of 16 months (range, 12 to 131 months). Although further study is needed, our findings suggest that conditioning with Flu/CY/TBI4Gy without ATG might allow stable engraftment in UCBT for adults with AA.

  52. Establishment of a Screening System to Identify Novel GATA-2 Transcriptional Regulators. 査読有り

    Keiichi Ohashi, Tohru Fujiwara, Koichi Onodera, Yo Saito, Satoshi Ichikawa, Masahiro Kobayashi, Yoko Okitsu, Noriko Fukuhara, Yasushi Onishi, Hideo Harigae

    The Tohoku journal of experimental medicine　244　(1)　41-52　2018年1月

    DOI： 10.1620/tjem.244.41 　

    ISSN：0040-8727

    詳細を見る 詳細を閉じる

    Hematopoietic stem cells can self-renew and differentiate into all blood cell types. The transcription factor GATA-2 is expressed in hematopoietic stem and progenitor cells and is essential for cell proliferation and differentiation. Heterozygous germline GATA2 mutations induce GATA-2 deficiency syndrome, characterized by monocytopenia, a predisposition to myelodysplasia and acute myeloid leukemia, and a profoundly reduced dendritic cell (DC) population, which is associated with increased susceptibility to viral infections. Because patients with GATA-2 deficiency syndrome could retain a wild-type copy of GATA-2, boosting residual wild-type GATA-2 activity may represent a novel therapeutic strategy for the disease. Here, we sought to establish a screening system to identify GATA-2 activators using human U937 monocytic cells as a potential model of the DC progenitor. Enforced GATA-2 expression in U937 cells induces CD205 expression, a marker of DC differentiation, indicating U937 cells as a surrogate of human primary DC progenitors. Transient luciferase reporter assays in U937 cells reveals a high promoter activity of the -0.5 kb GATA-2 hematopoietic-specific promoter (1S promoter) fused with two tandemly connected GATA-2 +9.9 kb intronic enhancers. We thus established U937-derived cell lines stably expressing tandem +9.9 kb/-0.5 kb 1S-luciferase. Importantly, forced GATA-1 expression, a repressor for GATA-2 expression, in the stable clones caused significant decreases in the luciferase activities. In conclusion, our system represents a potential tool for identifying novel regulators of GATA-2, thereby contributing to the development of novel therapeutic approaches.

  53. Successful treatment with allogeneic stem cell transplantation followed by DLI and TKIs for e6a2 BCR-ABL -positive acute myeloid leukaemia: A case report and literature review 査読有り

    Yasuhiko Harada, Satoshi Nishiwaki, Takumi Sugimoto, Koichi Onodera, Tatsunori Goto, Takahiko Sato, Sonoko Kamoshita, Naomi Kawashima, Aika Seto, Shingo Okuno, Satomi Yamamoto, Toshihiro Iwasaki, Yukiyasu Ozawa, Koichi Miyamura, Yoshiki Akatsuka, Isamu Sugiura

    Medicine (United States)　96　(50)　e9160　2017年12月1日

    出版者・発行元： Lippincott Williams and Wilkins

    DOI： 10.1097/MD.0000000000009160 　

    ISSN：1536-5964 0025-7974

  54. AIDA induction後に重症分化症候群(DS)を繰り返し発症し死亡したAPLの1例 化学療法減量による寛解導入死亡への影響について

    高橋 太郎, 李 尹河, 小野寺 晃一

    臨床血液　58　(4)　401-401　2017年4月

    出版者・発行元： (一社)日本血液学会-東京事務局

    ISSN：0485-1439

  55. Autoimmune-like hepatitis after allogeneic hematopoietic stem cell transplantation: humoral hepatic GvHD 査読有り

    D. Koyama, M. Ito, E. Yokohata, K. Watakabe, K. Onodera, T. Goto, A. Seto, K. Watanabe, M. Doisaki, Y. Ozawa, T. Yamaguchi, K. Miyamura

    BONE MARROW TRANSPLANTATION　52　(1)　151-153　2017年1月

    DOI： 10.1038/bmt.2016.202 　

    ISSN：0268-3369

    eISSN：1476-5365

  56. Hyperferritinemia after adult allogeneic hematopoietic cell transplantation: Quantification of iron burden by determining non-transferrin-bound iron 査読有り

    Tatsunori Goto, Katsuya Ikuta, Yoshihiro Inamoto, Sonoko Kamoshita, Emi Yokohata, Daisuke Koyama, Koichi Onodera, Aika Seto, Keisuke Watanabe, Nobuhiko Imahashi, Shokichi Tsukamoto, Yukiyasu Ozawa, Katsunori Sasaki, Masafumi Ito, Yutaka Kohgo, Koichi Miyamura

    International Journal of Hematology　97　(1)　125-134　2013年1月

    DOI： 10.1007/s12185-012-1252-1 　

    ISSN：0925-5710 1865-3774

  57. Clinical significance of hemophagocytosis in BM clot sections during the peri-engraftment period following allogeneic hematopoietic SCT 査読有り

    N. Imahashi, Y. Inamoto, M. Ito, D. Koyama, T. Goto, K. Onodera, A. Seto, K. Watanabe, M. Imahashi, S. Nishiwaki, S. Tsukamoto, T. Yasuda, Y. Ozawa, K. Miyamura

    BONE MARROW TRANSPLANTATION　47　(3)　387-394　2012年3月

    DOI： 10.1038/bmt.2011.95 　

    ISSN：0268-3369

︎全件表示 ︎最初の5件までを表示

講演・口頭発表等 139

  1. 再生不良性貧血に対する臍帯血移植と PTCY を用いたハプロ移植の比較

    大西 康, 森 毅彦, 山﨑 宏人, 平本 展大, 材木 義隆, 金谷 穣, 末永 孝生, 鬼塚 真仁, 青墳 信之, 内田 直之, 小野寺 晃一, 諫田 淳也, 中前 博久, 山本 隆介, 衛藤 徹也, 木村 貴文, 一戸 辰夫, 熱田 由子

    第45回日本造血･免疫細胞療法学会 総会 名古屋

  2. ブリナツモマブにより長期寛解を得た同種造血幹細胞移植後再発急性リンパ性白血病の2 症例

    小野寺, 晃一, 小松 弘香, 竹中 健太, 渡邉 樹也, 鳴海 善洋, 中村 嘉詞, 橋本 和貴, 櫻井 一貴, 内堀 雄介, 猪倉 恭子, 市川 聡, 福原 規子, 大西 康, 横山 寿行, 張替 秀郎

    第45回日本造血･免疫細胞療法学会 総会 名古屋

  3. 当院における FLU-BU-MEL あるいは FLU-MEL-TBI を強度減弱前処置に用いた臍帯血移植の後方視的比較

    橋本 和貴, 小野寺, 晃一, 大西 康, 内堀 雄介, 小松 弘香, 竹中 健太, 横山 寿行, 福原 規子, 市川 聡, 猪倉 恭子, 櫻井 一貴, 中村 嘉詞, 鳴海 善洋, 渡邊 樹也, 張替 秀郎

    第45回日本造血･免疫細胞療法学会 総会 名古屋

  4. Altered Transcription By GATA1 Impairs Autophagy and Prevents Ferroptosis in X-Linked Sideroblastic Anemia

    Koya Ono, Tohru Fujiwara, Hiroki Shima, Hironari Nishizawa, Chie Suzuki, Noriyuki Takahashi, Hiroki Kato, Koichi Onodera, Satoshi Ichikawa, Noriko Fukuhara, Yasushi Onishi, Hisayuki Yokoyama, Yukio Nakamura, Kazuhiko Igarashi, Hideo Harigae

    64th ASH Annual Meeting and Exposition

  5. Long-Term Hemoglobin Response and Reduction in Transfusion Burden Are Maintained in Patients with Pyruvate Kinase Deficiency Treated with Mitapivat

    Rachael F. Grace, Andreas Glenthøj, Wilma Barcellini, Madeleine Verhovsek, Jennifer A. Rothman, Marta Morado, D. Mark Layton, Oliver Andres, Frédéric Galactéros, Eduard J. van Beers, Koichi Onodera, Vip Viprakasi, Satheesh Chona, Malia P. Judge, Penelope A. Kosinski, Peter Hawkins, Sarah Gheuens, Emily Xu, Bryan McGee, PharmD, Vanessa Beynon, Hanny Al-Samkari

    64th ASH Annual Meeting and Exposition

  6. 優秀ポスター賞1 赤芽球におけるフェロケラターゼ（FECH）欠乏の環状鉄芽球形成への影響

    二階堂 舞香, 藤原亨, 小野浩弥, 加藤浩貴, 小野寺晃一, 市川聡, 福原規子, 大西康, 中村幸夫, 張替秀郎

    第８４回日本血液学会学術集会 福岡

  7. X連鎖性鉄芽球性貧血モデル細胞は分化過程でフェリチノファジーが障害される

    小野 浩弥, 藤原亨, 大地哲朗, 鈴木千恵, 高橋昇之, 加藤浩貴, 小野寺晃一, 市川聡, 福原規子, 大西康, 横山寿行, 中村幸夫, 張替秀郎

    第８４回日本血液学会学術集会 福岡

  8. SF3B1変異陽性の骨髄異形成症候群における環状鉄芽球形成機序の解明

    大地 哲朗, 藤原亨, 小野浩弥, 鈴木千恵, 二階堂舞香, 井上大地, 加藤浩貴, 小野寺晃一, 市川聡, 福原規子, 大西康, 横山寿行, 中村幸夫, 張替秀郎

    第８４回日本血液学会学術集会 福岡

  9. ALAS2遺伝子ヘテロ接合変異によるX連鎖性鉄芽球性貧血２例の検討

    小野 浩弥, 福原規子, 藤原実名美, 藤原亨, 鈴木千恵, 諸田直哉, 木葉大地, 田中悠也, 道又大吾, 猪倉恭子, 加藤浩貴, 小野寺晃一, 市川聡, 大西康, 横山寿行, 張替秀郎

    第８４回日本血液学会学術集会 福岡

  10. CAR-T治療後にトシリズマブおよびステロイド治療抵抗性のCRSを合併したB-ALLの一例

    大西 康, 小野寺晃一, 道又大吾, 田中悠也, 木葉大地, 諸田直哉, 小野浩弥, 猪倉恭子, 市川聡, 福原規子, 藤原亨, 横山寿行, 藤原実名美, 張替秀郎

    第８４回日本血液学会学術集会 福岡

  11. 特発性血小板減少性紫斑病に対するeltrombopag投与中に慢性骨髄性白血病を発症した1例

    諸田 直哉, 福原規子, 木葉大地, 田中悠也, 道又大吾, 小野浩弥, 猪倉恭子, 市川聡, 小野寺晃一, 大西康, 横山寿行, 張替秀郎

    第８４回日本血液学会学術集会 福岡

  12. 新規発症未分化多発性骨髄腫の２例

    市川 聡, 福原規子, 小野寺晃一, 大西康, 横山寿行, 藤島文喜, 一迫玲, 張替秀郎

    第８４回日本血液学会学術集会 福岡

  13. 組織学的形質転換を伴うMUM1陽性高グレード濾胞性リンパ腫はしばしば化学療法抵抗性を示す

    市川 聡, 渡邊正太郎, 福原規子, 小野寺晃一, 大西康, 横山寿行, 藤島史喜, 一迫玲, 張替秀郎

    第８４回日本血液学会学術集会 福岡

  14. Long-term outcome of patients with immune thrombocytopenia

    亀岡 淳一, 沖津庸子, 小林匡洋, 野村順, 阿部正理, 小野寺晃一, 市川聡, 福原規子, 大西康, 横山寿行, 藤原実名美, 高橋伸一郎, 張替秀郎

    第８４回日本血液学会学術集会 福岡

  15. Safety and efficacy of tisagenlecleucel in patients with relapsed or refractory DLBCL

    後藤 秀樹, 北脇 年雄, 藤井 伸治, 加藤 光次, 大西 康, 福原 規子, 山内 拓司, 虎谷 和則, 小林 宏紀, 吉田 匠汰, 下茂 雅俊, 小野寺 晃一, 千丈 創, 平田 健司, 横田 勲, 豊嶋 崇徳

    第８４回日本血液学会学術集会 福岡

  16. 芽球増加を伴う骨髄異形成症候群における同種移植前化学療法の意義：単施設の後方視的解析

    田中 悠也, 小野寺晃一, 木葉 大地, 諸田 直哉, 道又 大吾, 小野 浩弥, 猪倉 恭子, 市川 聡, 大西 康, 福原 規子, 横山 寿行, 張替 秀郎

    第44日本造血・免疫細胞療法学会学術集会 横浜/WEB

  17. 臍帯血移植時のGVHD予防におけるロイコボリンレスキューが移植成績に与える影響

    小野寺晃一, 木葉 大地, 諸田 直哉, 田中 悠也, 道又 大吾, 小野 浩弥, 猪倉 恭子, 市川 聡, 福原 規子, 大西 康, 横山 寿行, 張替 秀郎

    第44日本造血・免疫細胞療法学会学術集会 横浜/WEB

  18. 当院におけるCML-BCに対する同種造血幹細胞移植成績

    道又 大吾, 大西 康, 諸田 直哉, 木葉 大地, 田中 悠也, 小野 浩弥, 猪倉 恭子, 小野寺晃一, 市川 聡, 福原 規子, 横山 寿行, 張替 秀郎

    第44日本造血・免疫細胞療法学会学術集会 横浜/WEB

  19. 同種造血幹細胞移植後に急性GVHDによる結膜病変を来した2症例

    諸田 直哉, 小野寺晃一, 木葉 大地, 田中 悠也, 道又 大吾, 小野 浩弥, 猪倉 恭子, 市川 聡, 福原 規子, 大西 康, 横山 寿行, 張替 秀郎

    第44日本造血・免疫細胞療法学会学術集会 横浜/WEB

  20. 臍帯血移植後長期生存を得られた播種性フサリウム症合併急性骨髄性白血病の2例

    市川 聡, 福原 規子, 小野寺晃一, 大西 康, 横山 寿行, 張替 秀郎

    第44日本造血・免疫細胞療法学会学術集会 横浜/WEB

  21. Durability of Hemoglobin Response and Reduction in Transfusion Burden Is Maintained over Time in Patients with Pyruvate Kinase Deficiency Treated with Mitapivat in a Long-Term Extension Study

    Rachael F. Grace, Andreas Glenthoej, Wilma Barcellini, Madeleine Verhovsek, Jennifer A. Rothman, Marta Morado, D. Mark Layton, Oliver Andres, Frédéric Galactéros, Eduard J. Van Beers, Koichi Onodera, Vip Viprakasi, Satheesh Chona, John B. Porter, Malia P. Judge, Penelope A. Kosinski, Peter Hawkins, Sarah Gheuens, Emily Xu, Bryan McGee, Vanessa Beynon, Hanny Al-Samkari

    63nd ASH Annual Meeting and Exposition (オンライン)

  22. 播種性骨髄転移による血球減少を初発時に認めたがん腫の4 例

    市川 聡, 古川 瑛次郎, 道又 大吾, 猪倉 恭子, 小野寺 晃一, 福原 規子, 大西 康, 横山 寿行, 張替 秀郎

    第83回日本血液学会学術集会 仙台/WEB

  23. 非定型慢性骨髄性白血病移行期に対し化学療法により重症GVHD を伴いながら寛解に至った一例

    櫻井 一貴, 横山 寿行, 橋本 和貴, 猪倉 恭子, 市川 聡, 福原 規子, 小野寺 晃一, 張替 秀郎

    第83回日本血液学会学術集会 仙台/WEB

  24. ベンダムスチン, オビヌツズマブ療法後に潰瘍性大腸炎様の薬剤性大腸炎を発症した濾胞性リンパ腫の1 例

    猪倉 恭子, 福原 規子, 橋本 和貴, 櫻井 一貴, 道又 大吾, 古川 瑛次郎, 小野寺 晃一, 市川 聡, 大西 康, 横山 寿行, 張替 秀郎

    第83回日本血液学会学術集会 仙台/WEB

  25. 臍帯血移植におけるKIR リガンド不適合がGVHD 発症とNK 細胞遺伝子発現プロファイルに及ぼす影響

    横山 寿行, 渡邊 正太郎, 橋本 和貴, 櫻井 一貴, 道又 大吾, 古川 瑛次郎, 猪倉 恭子, 小野寺 晃一, 市川 聡, 齋藤 慧, 八田 俊介, 勝岡 優奈, 和泉 透, 鎌田 真弓遠宮, 靖雄, 原崎 頼子, 佐々木 治, 福原 規子, 大西 康, 張替 秀郎

    第83回日本血液学会学術集会 仙台/WEB

  26. Three-way translocation を有する悪性リンパ腫の臨床病理学的特徴

    渡邊 正太郎, 市川 聡, 福原 規子, 櫻井 一貴, 橋本 和貴, 古川 瑛次郎, 道又 大吾, 猪倉 恭子, 小野寺 晃一, 大西 康, 横山 寿行, 斎藤 陽, 八田 俊介, 鎌田 真弓, 大橋 圭一, 中嶌 真治, 菅原 知広, 藤島 史喜, 一迫 玲, 張替 秀郎

    第83回日本血液学会学術集会 仙台/WEB

  27. 優秀ポスター賞1 ろ胞性リンパ腫に対して同種造血幹細胞移植を施行した8 例；単施設の経験

    市川 聡, 齋藤 慧, 阿部 未玲, 福原 規子, 渡邊 正太郎, 櫻井 一貴, 橋本 和貴, 古川 瑛次郎, 道又 大吾, 猪倉 恭子, 小野寺 晃一, 大西 康, 横山 寿行, 藤原 実名美, 張替 秀郎

    第83回日本血液学会学術集会 仙台/WEB

  28. HLA-DRB1 の適合度が臍帯血移植後の治療成績に与える影響：単施設の後方視的解析

    小野寺 晃一, 櫻井 一貴, 橋本 和貴, 古川 瑛次郎, 道又 大吾, 猪倉 恭子, 市川 聡, 福原 規子, 大西 康, 横山 寿行, 張替 秀郎

    第83回日本血液学会学術集会 仙台/ WEB

  29. 骨髄性腫瘍における血清ビタミンB12 上昇の意義

    亀岡 淳一, 沖津 庸子, 小林 匡洋, 野村 順, 阿部 正理, 小野寺 晃一, 市川 聡, 福原 規子, 大西 康, 横山 寿行, 藤原 実名美, 高橋 伸一郎, 張替 秀郎

    第83回日本血液学会学術集会 仙台/WEB

  30. 成人EBV 陽性T/NK 細胞リンパ増殖性疾患に対する同種造血幹細胞移植の成績

    大西 康, 小野寺 晃一, 櫻井 一貴, 橋本 和貴, 道又 大吾, 古川 瑛次郎, 猪倉 恭子, 市川 聡, 福原 規子, 藤原 亨, 横山 寿行, 藤原 実名美, 張替 秀郎

    第83回日本血液学会学術集会 仙台/WEB

  31. 赤血球におけるFOG1 を介した転写制御ネットワークと糖代謝制御の関連

    藤原 亨, 鈴木 千恵, 小野 浩弥, 加藤 浩貴, 小野寺 晃一, 市川 聡, 福原 規子, 大西 康, 横山 寿行, 張替 秀郎

    第83回日本血液学会学術集会 仙台/WEB

  32. ヒト不死化赤血球前駆細胞株によるX 連鎖性鉄芽球性貧血モデル細胞株樹立の試み

    小野 浩弥, 藤原 亨, 齋藤 慧, 鈴木 千恵, 高橋 昇之, 加藤 浩貴, 小野寺 晃一, 市川 聡, 福原 規子, 大西 康, 横山 寿行, 中村 幸夫, 張替 秀郎

    第83回日本血液学会学術集会 仙台/WEB

  33. 優秀ポスター賞2 赤芽球ミトコンドリア代謝におけるFAM210B の意義の解明

    鈴木 千恵, 藤原 亨, 島 弘季, 小野 浩弥, 齋藤 慧, 加藤 浩貴, 小野寺 晃一, 市川 聡, 福原 規子, 大西 康, 横山 寿行, 中村 幸夫, 五十嵐 和彦, 張替 秀郎

    第83回日本血液学会学術集会 仙台/WEB

  34. 濾胞性リンパ腫と古典的ホジキンリンパ腫を同一患者で発症した4 例の臨床病理学的解析

    阿部 未玲, 福原 規子, 市川 聡, 櫻井 一貴, 橋本 和貴, 道又 大吾, 古川 瑛次郎, 渡邊 正太郎, 猪倉 恭子, 小野寺 晃一, 大西 康, 横山 寿行, 藤島 史喜, 一迫 玲, 張替 秀郎

    第83回日本血液学会学術集会 仙台/ WEB

  35. 当院MDS 症例におけるazacitidine 投与例の後方視的解析

    那須 健太郎, 小野寺 晃一, 中村 嘉詞, 大橋 圭一, 市川 聡, 高橋 太郎

    第83回日本血液学会学術集会 仙台/ WEB

  36. （優秀演題口演）当科における臓器移植後リンパ増殖性疾患の経験

    渡邊 正太郎, 福原 規子, 櫻井 一貴, 橋本 和貴, 古川 瑛次郎, 道又 大吾, 猪倉 恭子, 小野寺 晃一, 市川 聡, 大西 康, 横山 寿行, 藤島 史喜, 一迫 玲, 張替 秀郎

    第61回日本リンパ網内系学会総会（WEB)

  37. 同種臍帯血移植において KIR リガンド不適合が GVHD 予防法の効果に与える影響 The impact of KIR-ligand mismatch on the efficacy of GVHD-prophylaxis in cord blood transplantation

    横山 寿行, 櫻井 一貴, 橋本 和貴, 古川瑛次郎, 齋藤 慧, 八田 俊介, 猪倉 恭子, 小野寺晃一, 市川 聡, 福原 規子, 勝岡 優奈, 大西 康, 和泉 透, 張替 秀郎

    第43 回日本造血細胞移植学会総会 2021/3/5-7 東京/オンライン

  38. 同種造血幹細胞移植後に神経リンパ腫症として再発した濾胞性リンパ腫の 2 例 Two cases of relapsed follicular lymphoma as presenting neurolymphomatosis after allogenic HSCT

    阿部 未玲, 福原 規子, 櫻井 一貴, 橋本 和貴, 古川瑛次郎, 猪倉 恭子, 小野寺晃一, 市川 聡, 大西 康, 横山 寿行, 藤原実名美, 張替 秀郎

    第43 回日本造血細胞移植学会総会 東京/オンライン

  39. 非血縁者間骨髄移植前に Mogamulizumab 単剤治療を行った化学療法抵抗性 ATLL の 一例 A case of adult T-cell leukemia/lymphoma receiving mogamulizumab monotherapy preceding URBMT

    久保 龍大, 大西 康, 橋本 和貴, 櫻井 一貴, 猪倉 恭子, 古川瑛次郎, 小野寺晃一, 市川 聡, 福原 規子, 藤原 亨, 横山 寿行, 藤原実名美, 張替 秀郎

    第43 回日本造血細胞移植学会総会 2021/3/5-7 東京/オンライン

  40. レテルモビル予防終了後の CMV 再活性化の検討 Cytomegalovirus reactivation after letermovir prophylaxis in allogeneic HSCT

    古川瑛次郎, 大西 康, 橋本 和貴, 櫻井 一貴, 猪倉 恭子, 小野寺晃一, 市川 聡, 福原 規子, 横山 寿行, 藤原 亨, 藤原実名美, 張替 秀郎

    第43 回日本造血細胞移植学会総会 東京/オンライン

  41. P-177 レテルモビル予防終了後の CMV 再活性化の検討 Cytomegalovirus reactivation after letermovir prophylaxis in allogeneic HSCT

    古川瑛次郎, 大西 康, 橋本 和貴, 櫻井 一貴, 猪倉 恭子, 小野寺晃一, 市川 聡, 福原 規子, 横山 寿行, 藤原 亨, 藤原実名美, 張替 秀郎

    第43 回日本造血細胞移植学会総会 東京/オンライン

  42. P-096 非血縁者間骨髄移植前に Mogamulizumab 単剤治療を行った化学療法抵抗性 ATLL の 一例 A case of adult T-cell leukemia/lymphoma receiving mogamulizumab monotherapy preceding URBMT

    久保 龍大, 大西 康, 橋本 和貴, 櫻井 一貴, 猪倉 恭子, 古川瑛次郎, 小野寺晃一, 市川 聡, 福原 規子, 藤原 亨, 横山 寿行, 藤原実名美, 張替 秀郎

    第43 回日本造血細胞移植学会総会 東京/オンライン

  43. P-087 同種造血幹細胞移植後に神経リンパ腫症として再発した濾胞性リンパ腫の 2 例 Two cases of relapsed follicular lymphoma as presenting neurolymphomatosis after allogenic HSCT

    阿部 未玲, 福原 規子, 櫻井 一貴, 橋本 和貴, 古川瑛次郎, 猪倉 恭子, 小野寺晃一, 市川 聡, 大西 康, 横山 寿行, 藤原実名美, 張替 秀郎

    第43 回日本造血細胞移植学会総会 東京/オンライン

  44. O5-2 同種臍帯血移植において KIR リガンド不適合が GVHD 予防法の効果に与える影響 The impact of KIR-ligand mismatch on the efficacy of GVHD-prophylaxis in cord blood transplantation

    横山 寿行, 櫻井 一貴, 橋本 和貴, 古川瑛次郎, 齋藤 慧, 八田 俊介, 猪倉 恭子, 小野寺晃一, 市川 聡, 福原 規子, 勝岡 優奈, 大西 康, 和泉 透, 張替 秀郎

    第43 回日本造血細胞移植学会総会 東京/オンライン

  45. Transcriptional Regulation of Ferroptosis in X-Linked Sideroblastic Anemia Program: Oral and Poster Abstracts

    Koya Ono, Tohru Fujiwara, Kei Saito, Chie Suzuki, Noriyuki Takahashi, Yan Yan, Sayaka Sano, Koichi Onodera, Satoshi Ichikawa, Noriko Fukuhara, Yasushi Onishi, Hisayuki Yokoyama, Yukio Nakamura, Hideo Harigae

    62nd ASH Annual Meeting and Exposition（WEB)

  46. Mature γδT-cell leukemia complicated with agranulocytosis

    Satoshi Ichikawa, Kei Saito, Noriko Fukuhara, Hisayuki Yokoyama, Yuya Tanaka, Yoonha Lee, Koichi Onodera, Yasushi Onishi, Tohru Fujiwara, Fumiyoshi Fujishima, Ryo Ichinohasama, Hideo Harigae

    第82回日本血液学会学術集会 WEB

  47. Impact of ferroptosis in X-linked sideroblastic anemia

    Koya Ono, Tohru Fujiwara, Kei Saito, Chie Suzuki, Noriyuki Takahashi, Yan Yan, Sayaka Sano, Koichi Onodera, Satoshi Ichikawa, Noriko Fukuhara, Yasushi Onishi, Hisayuki Yokoyama, Yukio Nakamura, Hideo Harigae

    第82回日本血液学会学術集会 2020/10/10-11/8 WEB開催

  48. An autopsy case of γδ T cell clonal proliferation early after PD-1 blockade

    Koya Ono, Yasushi Onishi, Shotaro Watanabe, Kei Saito, Koichi Onodera, Satoshi Ichikawa, Noriko Fukuhara, Tohru Fujiwara, Hisayuki Yokoyama, Chie Suzuki, Hirofumi Watanabe, Mariko Oikawa, Yuto Yamazaki, Hideo Harigae

    第82回日本血液学会学術集会 2020/10/10-11/8 WEB開催

  49. The prognosis of FL with a concurrent DLBCL in the population-based lymphoma registry in Miyagi

    Shotaro Watanabe, Noriko Fukuhara, Hisayuki Yokoyama, Koichi Onodera, Satoshi Ichikawa, Yasushi Onishi, Yuna Katsuoka, Shunsuke Hatta, Kei Saito, Osamu Sasaki, Yoriko Harazaki, Mayumi Kamata, Yasuo Tomiya, Ryo Ichinohasama, Hideo Harigae

    第82回日本血液学会学術集会 WEB

  50. Clinical outcomes of commercial tisagenlecleucel for diffuse large B-cell lymphoma in our center

    Kei Saito, Satoshi Ichikawa, Koichi Onodera, Noriko Fukuhara, Yasushi Onishi, Hisayuki Yokoyama, Minami Fujiwara, Ken Sagou, Noriaki Tachi, Keiichi Ohashi, Hideo Harigae

    第82回日本血液学会学術集会 WEB

  51. Outcomes of allo-HCT using fludarabine-based regimens for Ph+ALL in complete molecular remission

    Yasushi Onishi, Koichi Onodera, Kazuki Hashimoto, Kazuki Sakurai, Eijiro Furukawa, Kyoko Inokura, Satoshi Ichikawa, Noriko Fukuhara, Tohru Fujiwara, Hisayuki Yokoyama, Minami Fujiwara, Hideo Harigae

    第82回日本血液学会学術集会 2020/10/10-11/8 WEB開催

  52. Switching from eltrombopag to romiplostim in patients with aplastic anemia: A report of three cases

    Koichi Onodera, Kazuki Hashimoto, Kazuki Sakurai, Eijiro Furukawa, Kyoko Inokura, Satoshi Ichikawa, Noriko Fukuhara, Yasushi Onishi, Hisayuki Yokoyama, Hideo Harigae

    第82回日本血液学会学術集会 2020/10/10-11/8 WEB開催

  53. Establishment of SF3B1 mutation screening based on high resolution melting analysis

    Chie Suzuki, Tohru Fujiwara, Tetsuro Ochi, Kei Saito, Koichi Onodera, Satoshi Ichikawa, Noriko Fukuhara, Yasushi Onishi, Hisayuki Yokoyama, Shinichi Fujimaki, Hideo Harigae

    第82回日本血液学会学術集会 2020/10/10-11/8 WEB開催

  54. Three cases of Philadelphia-positive acute leukemia presenting with deep venous thrombosis

    Kazuki Hashimoto, Yasushi Onishi, Koichi Onodera, Eijiro Furukawa, Kazuki Sakurai, Kyoko Inokura, Satoshi Ichikawa, Noriko Fukuhara, Tohru Fujiwara, Hisayuki Yokoyama, Minami Fujiwara, Hideo Harigae

    第82回日本血液学会学術集会 2020/10/10-11/8 WEB開催

  55. Two cases of central nervous system PTLD after ATG-based haploidentical HCT

    Eijiro Furukawa, Yasushi Onishi, Shinji Nakajima, Koichi Onodera, Kazuki Hashimo, Kazuki Sakurai, Kyoko Inokura, Satoshi Ichikawa, Noriko Fukuhara, Tohru Fujiwara, Hisayuki Yokoyama, Minami Fujiwara, Hideo Harigae

    第82回日本血液学会学術集会 2020/10/10-11/8 WEB開催

  56. PS-29-4 Two cases of central nervous system PTLD after ATG-based haploidentical HCT

    Eijiro Furukawa, Yasushi Onishi, Shinji Nakajima, Koichi Onodera, Kazuki Hashimot, Kazuki Sakurai, Kyoko Inokura, Satoshi Ichikawa, Noriko Fukuhara, Tohru Fujiwara, Hisayuki Yokoyama, Minami Fujiwara, Hideo Harigae

    第82回日本血液学会学術集会（WEB)

  57. PS-19-3 Three cases of Philadelphia-positive acute leukemia presenting with deep venous thrombosis

    Kazuki Hashimoto, Yasushi Onishi, Koichi Onodera, Eijiro Furukawa, Kazuki Sakurai, Kyoko Inokura, Satoshi Ichikawa, Noriko Fukuhara, Tohru Fujiwara, Hisayuki Yokoyama, Minami Fujiwara, Hideo Harigae

    第82回日本血液学会学術集会（WEB)

  58. PS-3-3 Switching from eltrombopag to romiplostim in patients with aplastic anemia: A report of three cases

    Koichi Onodera, Kazuki Hashimoto, Kazuki Sakurai, Eijiro Furukawa, Kyoko Inokura, Satoshi Ichikawa, Noriko Fukuhara, Yasushi Onishi, Hisayuki Yokoyama, Hideo Harigae

    第82回日本血液学会学術集会（WEB)

  59. OS-94-3 Outcomes of allo-HCT using fludarabine-based regimens for Ph+ALL in complete molecular remission

    Yasushi Onishi, Koichi Onodera, Kazuki Hashimoto, Kazuki Sakurai, Eijiro Furukawa, Kyoko Inokura, Satoshi Ichikawa, Noriko Fukuhara, Tohru Fujiwara, Hisayuki Yokoyama, Minami Fujiwara, Hideo Harigae

    第82回日本血液学会学術集会（WEB)

  60. OS-92-4 The impact of cytomegalovirus reactivation on outcomes in cord blood transplantation

    Hisayuki Yokoyama, Yuya Tanaka, Yoonha Lee, Kei Saito, Koichi Onodera, Satoshi Ichikawa, Mai Watanabe, Shunsuke Hatta, Yuna Katsuoka, Noriko Fukuhara, Yasushi Onishi, Kuniaki Meguro, Hideo Harigae

    第82回日本血液学会学術集会（WEB)

  61. OS-50-5 The prognosis of FL with a concurrent DLBCL in the population-based lymphoma registry in Miyagi

    Shotaro Watanabe, Noriko Fukuhara, Hisayuki Yokoyama, Koichi Onodera, Satoshi Ichikawa, Yasushi Onishi, Yuna Katsuoka, Shunsuke Hatta, Kei Saito, Osamu Sasaki, Yoriko Harazaki, Mayumi Kamata, Yasuo Tomiya, Ryo Ichinohasama, Hideo Harigae

    第82回日本血液学会学術集会（WEB)

  62. OS-56-2 Clinical outcomes of commercial tisagenlecleucel for diffuse large B-cell lymphoma in our center

    Kei Saito, Satoshi Ichikawa, Koichi Onodera, Noriko Fukuhara, Yasushi Onishi, Hisayuki Yokoyama, Minami Fujiwara, Ken Sagou, Noriaki Tachi, Keiichi Ohashi, Hideo Harigae

    第82回日本血液学会学術集会（WEB)

  63. OS-49-1 An autopsy case of γδ T cell clonal proliferation early after PD-1 blockade

    Koya Ono, Yasushi Onishi, Shotaro Watanabe, Kei Saito, Koichi Onodera, Satoshi Ichikawa, Noriko Fukuhara, Tohru Fujiwara, Hisayuki Yokoyama, Chie Suzuki, Hirofumi Watanabe, Mariko Oikawa, Yuto Yamazaki, Hideo Harigae

    第82回日本血液学会学術集会（WEB)

  64. PS-31-10 Mature γδT-cell leukemia complicated with agranulocytosis

    Satoshi Ichikawa, Kei Saito, Noriko Fukuhara, Hisayuki Yokoyama, Yuya Tanaka, Yoonha Lee, Koichi Onodera, Yasushi Onishi, Tohru Fujiwara, Fumiyoshi Fujishima, Ryo Ichinohasama, Hideo Harigae

    第82回日本血液学会学術集会（WEB)

  65. Molecular Characterization and Novel Therapeutic Strategy for X-Linked Sideroblastic Anemia Associated with ALAS2 Missense Variants

    61 st ASH Annual Meeting & Exposition Orange County Convention Center (OCCC), Orlando, FL

  66. Retrospective analysis of anthracycline-induced cardiotoxicity in a single center

    第81回日本血液学会学術集会

  67. Outcome of first alloSCT in adult patients with Phnegative B-ALL

    第81回日本血液学会学術集会

  68. Establishment of cellular model of X-linked sideroblastic anemia using homology-directed CRISPR/Cas9

    第81回日本血液学会学術集会

  69. Role of mitochondrial membrane protein FAM210B during erythroid differentiation

    第81回日本血液学会学術集会

  70. Preemptive therapy for CMV reactivation after daratumumab in patients with RRMM

    第81回日本血液学会学術集会 東京

  71. CRISPR/Cas9を用いたALAS2ミスセンス変異導入によるX連鎖性鉄芽球性貧血のモデル細胞

    小野浩弥, 高橋昇之, 藤原亨, 細川奈津子, 齋藤慧, 鈴木千恵, 小野寺晃一, 市川聡, 福原規子, 大西康, 張替秀郎

    第43回日本鉄バイオサイエンス学会学術集会 2019/9/20-21

  72. クローン病に合併したびまん性大細胞型B細胞リンパ腫再発に対して臍帯血移植を施行した一例

    古川瑛次郎, 福原規子, 中川諒, 川尻昭寿, 齋藤慧, 小野寺晃一, 市川聡, 大西康, 張替秀郎

    第59回日本リンパ網内系学会総会 出雲

  73. 臍帯血移植前に肺真菌症に対する外科的切除が有効であった急性骨髄性白血病3例

    中川諒, 大西康, 古川瑛次郎, 佐野沙矢香, 齋藤慧, 川尻昭寿, 小野寺晃一, 市川聡, 福原規子, 張替秀郎

    第41回日本造血細胞移植学会総会 大阪

  74. 成人発症の慢性活動性EBV感染症に対する臍帯血移植の成績

    大西康, 小野寺晃一, 中川諒, 佐野沙矢香, 川尻昭寿, 齋藤慧, 市川聡, 福原規子, 藤原亨, 藤原実名美, 張替秀郎

    第41回日本造血細胞移植学会総会 大阪

  75. 再生不良性貧血に対する同種造血幹細胞移植後にドナー型二次性着不全からAMLへと進展した一例

    小野寺晃一, 中川諒, 古川瑛次郎, 佐野沙矢香, 齋藤慧, 川尻昭寿, 市川聡, 福原規子, 大西康, 張替秀郎

    第41回日本造血細胞移植学会総会 大阪

  76. 成熟T細胞性リンパ腫に対する臍帯血移植：10例の報告

    佐野 沙矢香, 大西 康, 古川 瑛次郎, 中川 諒, 齋藤 慧, 川尻 昭寿, 小野寺 晃一, 市川 聡, 福原 規子, 張替 秀郎

    第80回日本血液学会学術集会 大阪

  77. T-LGL白血病に対するシクロスポリンA治療：単施設の経験

    大西 康, 藤原 実名美, 佐野 沙矢香, 中川 諒, 川尻 昭寿, 齋藤 慧, 小野寺 晃一, 市川 聡, 福原 規子, 藤原 亨, 張替 秀郎

    第80回日本血液学会学術集会 大阪

  78. The effect of TET2 disruption in human erythroid cells

    第９回日本血液学会国際シンポジウム2018in Kyoto

  79. Clinicopathological analysis of primary gastrointestinal T-cell lymphoma

    第79回日本血液学会学術集会 2017/10/20-22 東京

  80. Six Cases of acquired hemophilia A; Single center experience

    第79回日本血液学会学術集会 東京

  81. 同種末梢血幹細胞移植後多彩な自己抗体の出現を認め自己免疫疾患様の病態を呈した1例

    大友 瑞貴, 小野寺 晃一, 李 尹河, 高橋 太郎, 張替 秀郎

    臨床血液　2016年12月

  82. GATA2 regulates dendritic cell differentiation

    第78回日本血液学会学術集会 横浜

  83. GATA-2 Regulates Dendritic Cell Differentiation

    Koichi Onodera, Tohru Fujiwara, Yasushi Onishi, Ari Itoh-Nakadai, Yoko Okitsu, Noriko Fukuhara, Kenichi Ishizawa, Ritsuko Shimizu, masayuki Yamamoto, Hideo Harigae

    57th Annual Meeting&Exposition Orlando, FL

  84. 臍帯血移植後の顆粒球減少に伴う重症感染症に対して顆粒球輸血が奏功した1例

    福原 規子, 大橋 圭一, 長谷川 愼, 猪倉 恭子, 小野寺 晃一, 齋藤 陽, 中嶌 真治, 沖津 庸子, 木幡 桂, 勝岡 優奈, 大西 康, 石澤 賢一, 工藤 喜範, 峯岸 正好, 張替 秀郎

    日本輸血細胞治療学会誌　2013年12月

  85. 同種造血管細胞移植後にBacillus cereus 菌血症を呈した10例の検討

    八田俊介, 斎藤陽, 猪倉恭子, 小野寺晃一, 三浦由希子, 勝岡優奈, 木幡桂, 福原規子, 大西康, 徳田浩一, 石澤賢一, 亀岡淳一, 賀来満夫, 張替秀郎

    第３４回日本造血幹細胞移植学会総会 大阪

  86. 臍帯血移植後早期に非感染性胸水を合併した２例

    小野寺晃一, 斎藤陽, 八田俊介, 猪倉恭子, 三浦由希子, 木幡桂, 勝岡優奈, 福原規子, 大西康, 石澤賢一, 亀岡淳一, 張替秀郎

    第３４回日本造血幹細胞移植学会総会 大阪

  87. 臍帯血移植または非血縁者間骨髄移植を施行された成人急性骨髄性白血病および骨髄異形成症候群の成績：単一施設における比較解析

    大西康, 八田俊介, 斎藤陽, 猪倉恭子, 小野寺晃一, 三浦由希子, 木幡桂, 勝岡優奈, 福原規子, 石澤賢一, 亀岡淳一, 張替秀郎

    第３４回日本造血幹細胞移植学会総会 大阪

  88. 移植患者生涯手帳作成の試み

    宮村 耕一, 後藤 辰徳, 小野寺 晃一, 横畠 絵美, 小山 大輔, 渡邊 慶介, 瀬戸 愛花, 小澤 幸泰, 松本 公一, 加藤 剛二, 熱田 由子, 河野 彰夫, 村田 誠

    臨床血液　2011年9月

  89. 骨髄非破壊的前処置を用いた造血幹細胞移植後の卵巣機能の検討

    濱嶋 貴香, 横井 暁, 郡嶋 沙矢子, 中津 みどり, 坂堂 美央子, 新保 暁子, 左高 敦子, 齋藤 愛, 南 宏呂二, 廣村 勝彦, 堀 久美, 宮崎 顕, 吉田 加奈, 安藤 智子, 水野 公雄, 古橋 円, 石川 薫, 小野寺 晃一, 宮村 耕一

    東海産科婦人科学会雑誌　2011年3月

  90. 赤血球輸血依存性貧血から核型+1,der(1;7)(q10;p10),del(11)を伴う慢性好酸球性白血病へ移行した1例

    佐々木 了政, 小野寺 晃一, 濱田 宏之, 酒井 直, 宮入 泰郎, 佐藤 彰宜, 和野 雅治

    臨床血液　2009年9月

  91. 当施設における治療関連急性骨髄性白血病(tAML)の解析 10年間の経験

    濱田 宏之, 佐藤 彰宜, 小野寺 晃一, 鎌田 真弓, 佐々木 了政, 渡部 龍, 酒井 直, 宮入 泰郎, 和野 雅治

    臨床血液　2009年9月

  92. 末梢血幹細胞採取量に影響を与える因子の検討

    塚本 祥吉, 池口 美代子, 小山 大輔, 小野寺 晃一, 後藤 辰徳, 瀬戸 愛花, 渡邊 慶介, 今橋 伸彦, 小澤 幸泰, 宮村 耕一

    臨床血液　2009年9月

  93. Ph陽性急性リンパ性白血病に対する同種造血細胞移植施行群とイマチニブ併用化学療法継続群の治療成績の検討

    小澤 幸泰, 小山 大輔, 小野寺 晃一, 後藤 辰徳, 瀬戸 愛花, 渡邊 慶介, 今橋 伸彦, 塚本 祥吉, 宮村 耕一

    臨床血液　2009年9月

  94. 造血細胞移植後の腎合併症の検討

    渡邊 慶介, 青山 功, 小山 大輔, 後藤 辰徳, 小野寺 晃一, 瀬戸 愛花, 今橋 伸彦, 塚本 祥吉, 小澤 幸泰, 宮村 耕一

    臨床血液　2009年9月

  95. 当院におけるfludarabineとmelphalanを用いた減量強度前処置による同種造血幹細胞移植86例の検討

    後藤 辰徳, 小山 大輔, 小野寺 晃一, 瀬戸 愛花, 渡邊 慶介, 今橋 伸彦, 塚本 祥吉, 小澤 幸泰, 宮村 耕一

    臨床血液　2009年9月

  96. 当院におけるびまん性大細胞型B細胞性リンパ腫に対するrevised-IPIの有用性についての検討

    小野寺 晃一, 石川 泉, 井根 省二, 菅原 知広

    臨床血液　2008年9月

  97. 腫瘍細胞に核分葉、細胞質辺縁突起、ACP染色によりAuer小体様封入体を認めたBJPκ型多発性骨髄腫

    梅木 郁美, 濱田 宏之, 鎌田 真弓, 小野寺 晃一, 石川 泉, 酒井 直, 宮入 泰郎, 佐藤 彰宜, 和野 雅治

    臨床血液　2008年9月

  98. 単球増加、CRP上昇、発熱を主徴としたde novo CD5陽性び漫性大細胞型B細胞リンパ腫(CD5+DLBCL)

    鎌田 真弓, 濱田 宏之, 小野寺 晃一, 石川 泉, 酒井 直, 宮入 泰郎, 佐藤 彰宜, 和野 雅治

    臨床血液　2008年9月

  99. 血管内大型B細胞リンパ腫のFDG-PET偽陰性

    酒井 直, 鎌田 真弓, 小野寺 晃一, 濱田 宏之, 石川 泉, 佐藤 彰宜, 宮入 泰郎, 佐熊 勉, 和野 雅治

    臨床血液　2008年9月

  100. 特発性血小板減少性紫斑病(ITP)患者におけるピロリ菌除菌療法と"slow responder"の存在

    和野 雅治, 宮入 泰郎, 濱田 宏之, 鎌田 真弓, 小野寺 晃一, 石川 泉, 酒井 直, 佐藤 彰宜

    臨床血液　2008年9月

  101. 腹膜リンパ腫症を呈したびまん性大細胞型B細胞性リンパ腫の１例

    中村嘉詞, 市川聡, 齋藤慧, 福原規子, 小野寺晃一, 大西康, 横山寿行, 張替秀郎, 一迫玲

    第２２７回日本内科学会東北地方会 山形/zoom

  102. 難治性の出血性十二指腸潰瘍を合併した後天性血友病Aの１例

    鳴海善洋, 市川聡, 渡邉樹也, 中村嘉詞, 櫻井一貴, 小野寺晃一, 大西康, 福原規子, 横山寿行, 張替秀郎

    第２２７回日本内科学会東北地方会 山形/zoom

  103. 著明な血小板減少を伴った血管免疫芽球性T細胞リンパ腫の一例

    渡邉 樹也, 市川 聡, 鳴海 善洋, 中村 嘉詞, 櫻井 一貴, 猪倉 恭子, 小松 弘香, 竹中 健太, 橋本 和貴, 内堀 雄介, 小野寺 晃一, 福原 規子, 大西 康, 横山 寿行, 一迫 玲, 張替 秀郎

    第１３４回日本血液学会東北地方会 山形/ Zoom

  104. 高感度デジタルPCR法を用いて中枢神経再発を診断し得たMYD88 L265P変異陽性B細胞性リンパ腫の一例

    小松 弘香, 小野寺 晃一, 竹中 健太, 橋本 和貴, 内堀 雄介, 市川 聡, 大西 康, 福原 規子, 横山 寿行, 張替 秀郎

    第１３４回日本血液学会東北地方会 山形 / Zoom

  105. 寛解導入療法時にメトホルミンによる高乳酸血症を来したPh陽性急性リンパ性白血病の1例

    中村 捷, 道又 大吾, 木葉 大地, 田中 悠也, 小野寺 晃一, 市川 聡, 福原 規子, 大西 康, 横山 寿行, 張替 秀郎

    第226回日本内科学会東北地方会 仙台（WEB)

  106. Peritoneal lymphomatosisによって腹部コンパートメント症候群をきたしたB細胞性リンパ腫の一例

    田中 悠也, 小野寺 晃一, 木葉 大地, 諸田 直哉, 道又 大吾, 小野 浩弥, 猪倉 恭子, 市川 聡, 福原 規子, 大西 康, 横山 寿行, 一迫 玲, 張替 秀郎

    第133回日本血液学会東北地方会

  107. 持続勃起を契機に診断に至った慢性骨髄性白血病の1例

    市村 裕菜, 小野寺 晃一, 諸田 直哉, 田中 悠也, 道又 大吾, 市川 聡, 福原 規子, 大西 康, 横山 寿行, 張替 秀郎

    第225回日本内科学会東北地方会 WEB

  108. 完全房室ブロックを契機に診断に至ったびまん性大細胞型B細胞リンパ腫心臓浸潤の1例

    木葉 大地, 市川 聡, 道満 剛之, 田中 悠也, 猪倉 恭子, 福原 規子, 横山 寿行, 鈴木 秀明, 安田 聡, 張替 秀郎

    第224回日本内科学会東北地方会 WEB

  109. 同種造血幹細胞移植後の菌血症に対しバック法で採取した顆粒球輸血を行った 2 症例

    横山寿行, 諸田直哉, 木葉大地, 田中悠也, 道又大吾, 小野浩弥, 猪倉恭子, 小野寺晃一, 市川聡, 福原規子, 大西康, 島貫美和子, 関 修, 成田香魚子, 藤原実名美, 張替秀郎

    第 119 回日本輸血・細胞治療学会東北支部例会 WEB

  110. CD45かつCD30陽性のため悪性リンパ腫と鑑別を要した未分化神経内分泌腫瘍の1例

    諸田 直哉, 小野寺 晃一, 齋藤 良太, 道又 大吾, 猪倉 恭子, 市川 聡, 福原 規子, 大西 康, 横山 寿行, 張替 秀郎

    第223回日本内科学会東北地方会 WEB

  111. 血球貪食症候群を伴い発症したTCR陰性末梢性T細胞リンパ腫、非特定型の一例

    澤田 拓実, 諸田 直哉, 小野 浩弥, 道又 大吾, 小野寺 晃一, 市川 聡, 福原 規子, 大西 康, 横山 寿行, 張替 秀郎

    第132回 日本血液学会 東北地方会 福島（WEB)

  112. 血球貪食症候群を伴い発症したTC;陰性末梢性T細胞リンパ腫;非特定型の一例

    澤田 拓実, 諸田 直哉, 小野 浩弥, 道又 大吾, 小野寺 晃一, 市川 聡, 福原 規子, 大西 康, 横山 寿行, 張替 秀郎

    第132回日本血液学会東北地方会 福島（WEB)

  113. CRAB症候にて発症した骨髄原発B細胞リンパ腫の一例

    道満 剛之, 市川 聡, 猪倉 恭子, 櫻井 一貴, 木葉 大地, 田中 悠也, 福原 規子, 横山 寿行, 小野寺 晃一, 大西 康, 張替 秀郎

    第132回日本血液学会東北地方会 福島（WEB)

  114. BCR-ABL1陽性急性骨髄性白血病（AML with BCR-ABLの2例

    櫻井一貴, 勝岡優奈, 横山寿行, 斎藤慧, 八田俊介, 猪倉恭子, 市川聡, 福原規子, 小野寺晃一, 大西康, 和泉透, 張替秀郎

    第132回日本血液学会東北地方会 福島（WEB)

  115. 移植後早期再発した急性巨核芽球性白血病に対して臍帯血移植を行い長期寛解を達成した一例

    櫻井 一貴, 市川 聡, 齋藤 慧, 猪倉 恭子, 福原 規子, 横山 寿行, 小野寺 晃一, 大西 康, 藤原 亨, 亀岡 淳一, 張替 秀郎

    第131回日本血液学会東北地方会 （WEB)

  116. 再発難治性浸潤性胸腺腫に併発した赤芽球癆に対してシクロスポリンが著効した1例

    橋本 和貴, 市川 聡, 古川 瑛次郎, 猪倉 恭子, 小野寺 晃一, 福原 規子, 大西 康, 横山 寿行, 高橋 昌宏, 張替 秀郎

    第222回日本内科学会東北地方会 WEB

  117. 気道感染を契機に重篤な出血症状を伴って発症した後天性第X因子欠乏の1例

    八木 櫻子, 市川 聡, 齋藤 慧, 福原 規子, 小野寺 晃一, 大西 康, 横山 寿行, 藤原 実名美, 張替 秀郎

    第221回日本内科学会東北地方会 秋田

  118. 腑帯血移植により持続的寛解を得られた治療抵抗性血管免疫芽球性T細胞リンパ腫の一例

    本江史門, 市川聡, 福原規子, 齋藤慧, 小野寺晃一, 大西康, 横山寿行, 張替秀郎

    第130回日本血液学会東北地方会 秋田

  119. Comparison of the outcomes between cord blood transplantation and BMT/PBSCT from young or elderly donors

    第42回日本造血細胞移植学会総会（開催中止・誌上発表）

  120. SAA に対するuBMT 後に、肝多発腫瘤で発症しR-EPOCH 療法が有効であったPTLD の1 例

    中川 諒, 大西 康, 小野寺晃一, 田中悠也, 李 尹河, 齋藤 慧, 市川 聡, 藤原 亨, 福原 規子, 横山 寿行, 藤原実名美, 張替 秀郎

    第42回日本造血細胞移植学会総会（開催中止・誌上発表）

  121. 直接作用型抗ウイルス薬治療後のHCV 再活性化を認めた急性骨髄性白血病に対する臍帯血移植の一例

    田中悠也, 李 尹河, 齋藤 慧, 小野寺晃一, 市川 聡, 福原規子, 大西 康, 横山寿行, 張替秀郎

    第42回日本造血細胞移植学会総会（開催中止・誌上発表）

  122. 臍帯血移植後の末梢血単球絶対数が移植成績に及ぼす影響

    小野寺晃一, 田中悠也, 李 尹河, 齋藤 慧, 市川 聡, 福原規子, 大西 康, 横山寿行, 張替秀郎

    第42回日本造血細胞移植学会総会（開催中止・誌上発表）

  123. 急性骨髄性白血病においてHLA-DR の発現が同種移植の予後に与える影響についての検討

    李 尹河, 田中悠也, 齋藤 慧, 小野寺晃一, 市川 聡, 福原規子, 大西 康, 横山寿行, 張替秀郎

    第42回日本造血細胞移植学会総会（開催中止・誌上発表）

  124. 節外性NK/T 細胞リンパ腫の同種移植後早期再発に対して短期L-asparaginase 投与が 著効した一例

    市川 聡, 福原 規子, 齋藤 慧, 横山 寿行, 田中 悠也, 李 尹河, 小野寺 晃一, 大西 康, 一迫 玲, 張替 秀郎

    第129回日本血液学会東北地方会

  125. ルキソリチニブ投与中に低悪性度B細胞性リンパ腫を発症した原発性骨髄線維症の1例

    戒能 明, 小野寺晃一, 田中悠也, 李 尹河, 齋藤 慧, 市川 聡, 福原規子, 大西 康, 横山寿行, 張替秀郎

    第219回日本内科学会東北地方会

  126. MelDex療法にて臓器障害が改善し安全に自家末梢血幹胞移植を施行し得た全身性ALアミロイドーシスの1例

    山口知暁, 小野寺晃一, 田中悠也, 李 尹河, 齋藤 慧, 市川 聡, 福原規子, 大西 康, 横山寿行, 張替秀郎

    第218回日本内科学会東北地方会 青森

  127. 診断・治療に苦慮したメソトレキセート関連ホジキンリンパ腫の１例

    岩渕蒼太, 市川聡, 齋藤慧, 小野寺晃一, 白井剛志, 福原規子, 大西康, 藤井博司, 張替秀郎

    第217回日本内科学会東北地方会

  128. 関節リウマチを合併した慢性骨髄性白血病に対してダサチニブ治療後に無治療寛解を達成した一例

    高橋 彩理, 大西 康, 小野寺 晃一, 市川 聡, 藤原 亨, 福原 規子, 石井 智徳, 張替 秀郎

    医学生研修医の日本内科学会ことはじめ2019名古屋

  129. 全身性AAアミロイドーシスを伴って発症したホジキンリンパ腫の一例

    宍戸 愛, 福原 規子, 古川 瑛次郎, 佐野 沙矢香, 齋藤 慧, 小野寺 晃一, 市川 聡, 大西 康, 長澤 将, 張替 秀郎

    医学生研修医の日本内科学会ことはじめ2019名古屋

  130. 腫瘤を形成し悪性リンパ腫との鑑別を要したIgG4関連肥厚性硬膜炎の一例

    渡邉 樹也, 小野寺 晃一, 古川 瑛次郎, 中川 諒, 川尻 昭寿, 齋藤 慧, 市川 聡, 福原 規子, 大西 康, 張替 秀郎

    医学生研修医の日本内科学会ことはじめ2019名古屋

  131. Daratumumab併用療法後にCD38陰性化を伴って病勢増悪を来した再発難治性多発性骨髄腫の一例

    齋藤 慧, 古川 瑛次郎, 佐野 沙矢香, 中川 諒, 川尻 昭寿, 小野寺 晃一, 市川 聡, 大西 康, 福原 規子, 張替 秀郎

    第127回日本血液学会東北地方会

  132. 尿酸66mg/dlを伴う腫瘍崩壊症候群で発症し,救命し得たB細胞リンパ腫の１例

    橋本和貴, 佐野沙矢香, 中川 諒, 齋藤 慧, 川尻昭寿, 小野寺晃一, 市川 聡, 福原規子, 大西 康, 張替秀郎

    第215回日本内科学会東北地方会 仙台

  133. 巨大な膵形質細胞腫を伴った再発難治性多発性骨髄腫の1例

    古川 瑛次郎, 市川 聡, 福原 規子, 齋藤 慧, 佐野 沙矢香, 中川 諒, 川尻 昭寿, 小野寺 晃一, 大西 康, 張替 秀郎

    第126回日本血液学会東北地方会 仙台

  134. 抗CCP抗体陽性、好中球減少を認めた貧血の1例

    齋藤孝晴, 髙橋太郎, 渡邊正太郎, 小野寺晃一

    第214回日本内科学会東北地方会

  135. 急性骨髄性白血病および骨髄異形成症候群に対する臍帯血移植の成績：前処置法と病期の影響

    渡邉真威, 大西康, 氷室真仁, 小野寺晃一, 突田真紀子, 小林匡洋, 沖津庸子, 福原規子, 藤原亨, 藤原実名美, 張替秀郎

    第38回日本造血細胞移植学会総会 名古屋

  136. Leukocytosisを呈しBRAF V600E変異陽性のHairy cell leukemia-variantの１例

    金 美賢, 高橋 太郎, 市川 聡, 小野寺 晃一, 坂元 和宏, 一迫 玲

    第121回日本血液学会東北地方会

  137. 再発急性骨髄性白血病に対して3回目の同種造血幹細胞移植をHLA半合致ドナーかた施行した1例

    渡邊正太郎, 大西康, 渡邉真威, 氷室真仁, 小野寺晃一, 突田真紀子, 小林匡洋, 沖津庸子, 福原規子, 張替秀郎

    第206回日本内科学会東北地方会 福島

  138. 自己末梢血幹細胞移植後に発症したEBV関連リンパ増殖性疾患

    渡邉真威, 突田真紀子, 鈴木琢磨, 齋藤慧, 氷室真仁, 小野寺晃一, 小林匡洋, 沖津庸子, 福原規子, 大西康, 亀岡淳一, 張替秀郎

    第120回日本血液学会 東北地方会 福島

  139. 腹水貯留で再発し消化管穿孔を合併したＴリンパ芽球性リンパ腫の１例

    大橋圭一, 鈴木真紀子, 中嶌真治, 八田俊介, 小野寺晃一, 勝岡優奈, 大西康, 一迫玲, 石澤賢一, 張替秀郎

    第196回日本内科学会東北地方会

︎全件表示 ︎最初の5件までを表示

共同研究・競争的資金等の研究課題 2

  1. GATA-2を介した炎症性サイトカインの産生制御機構の解明 競争的資金

    小野寺 晃一

    提供機関：Japan Society for the Promotion of Science

    制度名：Grants-in-Aid for Scientific Research Grant-in-Aid for Young Scientists (B)

    研究種目：Grant-in-Aid for Young Scientists (B)

    研究機関：Tohoku University

    2017年4月1日 ～ 2019年3月31日

    詳細を見る 詳細を閉じる

    MonoMAC症候群は、単球および樹状細胞欠損を特徴とし、非定型抗酸菌感染症、骨髄異形成症候群や急性骨髄性白血病の発症を来す疾患である。MonoMAC症候群では片方のアリルのGATA2遺伝子変異によるGATA2タンパク質の量的異常を呈していることが原因であるため、野生型GATA2タンパク質の発現を誘導する事が治療戦略の１つとなり得る。しかしながら、現在のところ、GATA2遺伝子の上流の制御機構については十分に明らかになっていない。本研究では樹状細胞の一部が単球から分化していることに着目し、単球細胞株U937を用いてGATA2遺伝子の発現レベルを評価するバイオアッセイ系の構築に成功した。

  2. 樹状細胞分化におけるGATA2の機能同定－MonoMac症候群の病態解明－

    大西 康, 小野寺 晃一

    提供機関：Japan Society for the Promotion of Science

    制度名：Grants-in-Aid for Scientific Research Grant-in-Aid for Young Scientists (B)

    研究種目：Grant-in-Aid for Young Scientists (B)

    研究機関：Tohoku University

    2014年4月1日 ～ 2017年3月31日

    詳細を見る 詳細を閉じる

    MonoMAC症候群の責任遺伝子であるGATA2が免疫応答の中心となる樹状細胞の分化において果たす役割を解析した。GATA2の欠失により骨髄球系共通前駆細胞および樹状細胞共通前駆細胞からの樹状細胞分化が障害された。さらに、GATA2が骨髄球系前駆細胞においてGATA3などT細胞分化に関連する遺伝子発現を抑制した。GATA2が造血幹細胞の維持・増殖だけではなく、血球の分化過程でも重要な役割を果たすことが示された。